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Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian 
cancer, with the full potential yet to be proven. To facilitate IP chemotherapy of ovarian 
cancer, we have developed a nanoparticle depot for IP chemotherapy consisted of 
paclitaxel (PTX) nanocrystals (PNC) and hyaluronic acid-based hydrogel (HA gel). PNC 
with a size of ~310 nm was produced by nonsolvent and temperature-induced 
crystallization. Dissolution kinetics of PNC could be determined by the light scattering 
method rather than the dialysis method due to drug reprecipitation caused by diffusion 
barrier. PTX release profiles from PNC-gel and PTX precipitate-gel (PPT-gel) were 
estimated in both sink- and non-sink conditions, where the latter simulated the peritoneal 
environment. In-vitro release kinetics studies did not reveal any difference between PNC-
gel and PPT-gel, partly due to the centrifugation-related artifacts.  
In cellular toxicity test and maximum tolerated dose assessment, PNC-gel 
provided more efficient killing effect and greater toxicity than PPT-gel, which contained 
larger PTX particles, indicating a greater dissolution rate of PNC due to the small size. A 
single IP administration of PNC-gel extended the survival of mice with IP tumors 
significantly better than the same dose Taxol, due to the local depot effect, whereas PPT-  
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gel was not superior to Taxol in survival extension. While the cell toxicity test and in-
vivo results consistently point to the beneficial effect of particle size reduction, in-vitro 
drug release kinetics did not predict the difference between PPT- and PNC-gels, 
suggesting the limitation of current release study methods. 
 For PNC-gel to serve the cancer patients to its full potential, the compatibility 
between PNC and HA gel could be optimized by incorporating hydrophobic domains in 
the hydrogel and introducing surface stabilizer on PNC to achieve a well-controlled 
release. Aminoethyl 5β-cholanoamide (EtCA) was conjugated to one of the gel 
precursors, and the in-vitro PTX release was enhanced by the inclusion of EtCA. 
However, it was not pursued in the subsequent studies due to the unexpected toxicity of 
EtCA. Albumin-stabilized PNC with a sub-200 nm particle size were prepared using a 
method involving incipient crystallization in polymer matrix and subsequent surface 
stabilization with albumin. The function and quantitation of surface stabilizers need 
further investigation. In-vitro dissolution test and bioactivity evaluation of Cim-alb 
remains to be performed to test the contribution of small size to enhancing local 




CHAPTER 1. INTRODUCTION1 
1.1 Background 
The mainstay of current peritoneal malignancy treatment is surgical debulking of 
visible tumors and post-surgical chemotherapy to remove residual microscopic tumors [1-
3]. Recently, intraperitoneal (IP) chemotherapy has been pursued in post-surgical 
management of peritoneal malignancies, due to the promise of a high local concentration 
and a longer half-life of a drug in the peritoneal cavity, which provides a unique 
opportunity for the locoregional treatment of the IP malignances [4-6]. Part of the IP-
administered drugs are absorbed to systemic circulation, but it occurs at a slower rate 
than those administered intravenously [7-9]; therefore, IP dosage forms can also serve as 
a depot for sustained systemic drug delivery. IP chemotherapy has proven significantly 
more effective than intravenous (IV) therapy in several clinical studies [1, 3, 10]. 
Accordingly, the National Cancer Institute issued a clinical alert to recommend IP 
chemotherapy for stage III patients with optimally debulked ovarian cancer in 2006 [11].  
On the other hand, several challenges remain to be overcome before IP 
chemotherapy to make a standard protocol for post-surgical management of peritoneal 
                                                 
1 The content of this chapter has been previously published in Ceeln, W.P. and Levine, E.A., eds., 
Intraperitoneal Cancer Therapy: Principles and Practice. CRC Press/Taylor & Francis Group, Boca Raton, 
FL, 2016.  
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malignancies. For example, IP-administered drugs show limited penetration into tumors 
[12], thus necessitating the use of high IP doses. The high IP doses in turn account for 
increased toxicities such as myelotoxicity, neurotoxicity, nephrotoxicity, nausea, 
vomiting, and abdominal pain [11, 13, 14]. Cumulative toxicities reduce options for 
subsequent rounds of therapy [15]. Moreover, complications related to IP administration, 
such as discomfort due to prolonged infusion, catheter implantation, and peritoneal 
adhesion, result in poor quality of life and, thus, high rate of dropout prior to the 
completion of planned treatment [1, 14].  
While the long list of challenges seems discouraging, this leaves the formulation 
scientists with several questions: Can drug delivery systems help overcome any of these 
problems? What are the unique requirements for IP drug delivery?  What needs to be 
done and what has been done to improve drug delivery to the peritoneal cavity? In this 
chapter, we intend to address these questions by reviewing recent literature concerning IP 
drug delivery. We will discuss experimental approaches to improve the effectiveness of 
IP chemotherapy, focusing on the biomaterials used as drug carriers and various dosage 
forms that have been reported to date. The chapter will conclude with a discussion of 
remaining challenges and future perspectives. 
 
1.2 Materials for IP Delivery Systems 
1.2.1 Requirements for IP Drug Carriers 
Typical first-line chemotherapeutic agents such as paclitaxel (PTX), docetaxel 
(DTX) and cisplatin are low molecular weight drugs (<20 kDa), which are absorbed 
3 
 
through the peritoneal capillaries and enter the systemic circulation in a few hours [7-9]. 
The short residence time not only compromises the effectiveness of local chemotherapy 
but also requires frequent or continuous dosing, culminating in complications related to 
catheters and infection [16]. For the delivery of low molecular weight drugs, it is 
therefore important to attenuate fast systemic absorption and maintain a high local 
concentration of a drug. Ideally, the IP drug carriers should provide a sustained drug 
release to maintain the local drug concentration within an effective range over several 
weeks. The sustained local delivery of chemotherapy is also found beneficial for avoiding 
tumor repopulation, which can occur during drug-free cycles in conventional intermittent 
therapy [17]. In addition, it is desirable that the carriers are degraded into molecules that 
are readily absorbed and cleared from the body by the time the loaded drug is exhausted 
so that surgical removal of empty carriers may not be necessary. 
While the primary goal of the IP delivery system is to remain in the peritoneal 
cavity and provide a local reservoir of a drug for a prolonged period, such an effort often 
faces a challenge due to the sensitivity of the peritoneal cavity to foreign materials. The 
peritoneal cavity is responsible for protecting the body from breaches in the integrity of 
the gut; therefore, it is armed with powerful innate and adaptive immune mechanisms 
[18]. When confronted by an insult, peritoneal mesothelial cells, polymorphonuclear 
neutrophils, and the resident peritoneal-associated lymphoid tissues interact with one 
another via chemical signaling to produce inflammatory responses to the foreign 
materials [18]. Due to this sensitivity, some biomaterials typically considered 
biocompatible are found to induce significant inflammatory responses such as peritoneal 
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adhesions [19, 20]. Therefore, in designing an IP drug delivery system, it is necessary to 
apply more stringent criteria for the selection of biomaterials for formulations. 
 
1.2.2 Biomaterials for IP Drug Delivery 
A list of polymers used for other biomedical applications is a good starting point 
for selection of drug carrier materials. In particular, biomaterials used for peritoneal 
adhesion prevention are great candidates for IP drug delivery. Several natural and 
synthetic polymers have been used clinically and experimentally as physical barrier 
devices, as reviewed elsewhere in detail [21].  
 
1.2.2.1 Natural Polymers  
Polysaccharides such as hyaluronic acid (HA) [22-26], cellulose derivatives [26-
28], dextran [29-31], and chitosan [20, 32, 33] have been explored for IP application. The 
popularity of these polysaccharides stems from the biocompatibility proven in various 
biomedical applications. The polysaccharides are chemically modified into reactive 
precursors, which can form crosslinkable hydrogels upon application [20, 34, 35]. For 
example, HA is modified into two types of precursors - one with adipic dihydrazide and 
the other oxidized to have aldehydes, which instantly form a hydrogel upon contact [25]. 
The polysaccharide-based hydrogels are enzymatically degraded; therefore, the 
degradation rate can be controlled by combining polymers with different enzyme 
susceptibility. For example, the degradation rate of HA gel in the peritoneal cavity was 
extended by replacing one of the gel precursors with cellulose derivatives, which were 
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not degraded by human enzymes [35]. For the delivery of hydrophobic drugs, it is likely 
necessary to balance the hydrophobicity and hydrophilicity of the polymer [36]. For this 
purpose, it is conceivable to modify the polymer with hydrophobic moieties to increase 
the compatibility between drugs and polymers [37, 38]. Chitosan has also been widely 
explored as a local depot of chemotherapeutic agents, where various stimuli (light, pH, 
temperature) are employed as a trigger to form a hydrogel in-situ [39].  
 
1.2.2.2 Synthetic Polymers 
Synthetic polymers used for the prevention of peritoneal adhesion and IP 
chemotherapy include polylactic acid (PLA), poly(lactide-co-glycolide) (PLGA), 
polyethylene glycol (PEG), poly(Ɛ-caprolactone) (PCL) and their block co-polymers [26, 
40-44]. Most of these polymers are commercially available at reasonable prices. In 
particular, PLGA is widely used as a drug carrier [45] or a device [46, 47] because of its 
track record in the approved products and the well-known biodegradability and 
biocompatibility [21]. An advantage of synthetic polymers over natural polymers is that it 
is relatively easier to control the molecular weight, monomer composition, and structure 
of the polymer; therefore, there is greater flexibility in delivering various types of drugs 
[43, 44].  
 
1.3 Dosage Forms for IP Drug Delivery 
The most common form of IP chemotherapy is the repurposed IV solutions. To 
increase the drug retention in the peritoneal cavity, viscous polymer solutions, micro- or 
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nanoparticle formulations, implantable polymeric depots, and hydrogel-based systems 
have been explored [21, 34, 48, 49].  
 
1.3.1 Solutions 
PTX is poorly water-soluble and, thus, requires a solubility enhancer. An equal 
parts mixture of ethanol and Cremophor EL (polyethoxylated castor oil) is used to 
solubilize PTX in Taxol® [50, 51]. Alternative solubilization strategies are pursued to 
reduce toxicities related to Cremophor EL. For example, PTX and randomly methylated- 
β-cyclodextrin (RAME-β-CD) form water-soluble inclusion complexes, which does not 
precipitate upon dilution and stay stable after 24 h storage at ambient temperature or 2 h 
at 41.5 °C [52]. When used for hyperthermic peritoneal perfusion, PTX/RAME-β-CD 
complexes showed 40-fold higher plasma concentration than Taxol in a rat model [53] 
and delayed the growth of peritoneal carcinomatosis [54]. The authors argued that 
PTX/RAME-β-CD complexes had a greater ability to penetrate into IP tumors than Taxol, 
which entrapped PTX in surfactant micelles and thus limited direct tumor exposure of the 
drug [53]. 
A viscous solution of hydroxyethyl starch was used for the IP delivery of PTX [55] 
and DTX [56]. Sprague Dawley rats were administered IP with the taxane compounds 
using 6% hydroxyethyl starch (hetastarch) or 1.5% dextrose peritoneal dialysis solution 
as a carrier. Fluid clearance and mean taxane concentrations in plasma were lower when 
the drugs were delivered with hetastarch solution than with the peritoneal dialysis 
solution. Importantly, the total amount of drug remaining in the peritoneal cavity was 
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significantly higher with hetastarch solution [55, 56]. These studies demonstrate that 
hetastarch solution helped retain taxane compounds in the peritoneal cavity and reduce 
systemic exposure to the drugs. 
 
1.3.2 Micro- or Nanoparticles 
A tumor penetrating microparticles (TPM) loaded with PTX was designed for IP 
drug delivery [49]. The TPM system consisted of two types of particles. One was priming 
TPM, which encapsulated PTX in a low molecular weight PLGA (LA:GA=50:50) and 
released the drug rapidly to “prime” the tumors: i.e., to expand the interstitial space via 
apoptosis induction and enhance the penetration of the second type of particles into 
tumors. The second component called sustaining TPM encapsulated PTX in a high 
molecular weight PLGA (LA:GA=75:25) and, thus, provided sustained drug release to 
kill tumor cells. TPMs were able to retain in the peritoneal cavity for a longer time, 
achieve greater therapeutic effect and lower toxicity than Taxol [49]. The tumor-priming 
technology was later used to promote the delivery of survivin siRNA, which targeted a 
gene encoding survivin, an anti-apoptotic protein associated with metastases and poor 
prognosis of patients with gastric and colorectal cancers [57]. Here, siRNA was 
encapsulated in PEGylated cationic liposomes (PCat) were administered IP after TPM 
treatment of IP tumors. The combination of PTX-loaded TPM and PCat-siSurvivin was 
more effective than each treatment in suppressing tumor growth due to the synergy of the 
two treatment: TPM enhancing the penetration of PCat-siSurvivin into peritoneal tumors 
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and PCat-siSurvivin reducing survivin expression and augmenting TPM-induced anti-
proliferation and apoptosis [57].   
A nanocrystal (NC) form (sub-micron drug particles stabilized by surfactants 
and/or polymers) of PTX has been used in conjunction with hyperthermia for IP 
chemotherapy [58]. PTX NCs were produced using Pluronic F127 as a stabilizer and 
administered to rats bearing peritoneal tumors via IP perfusion at 41.5°C for 45 min. The 
PTX NCs showed similar anti-tumor activity as Taxol with relatively low apparent 
toxicity [58]. Unlike Taxol, the blood level of PTX continued to increase even after the 
discontinuation of NC HIPEC, which suggests the long-term residence of NCs in the 
peritoneal cavity due to their mucoadhesive properties [58].  
Polymeric micelles have been used for delivery of multiple drugs to IP tumors 
[42]. A combination of three drugs with distinct mechanisms of action-PTX as a 
cytotoxic drug, cyclopamine (CYP) as an inhibitor of hedgehog signaling to reverse 
taxane resistance, and gossypol (GSP) as a proapoptotic compound-was encapsulated in 
poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles for co-delivery 
to tumors. Simultaneous encapsulation of three drugs in a single polymeric micelle was 
possible as they have similarly poor water solubility [42]. The 3-drug loaded micelles 
were able to disaggregate three dimensional spheroids of ES-2 human ovarian cancer 
cells, whereas micelles with a single-drug or 2-drug combination showed negligible 
effects on tumor spheroids. In mouse models of IP xenograft, the IP administered 3-drug 
micelles reduced tumor burden to a greater extent than PTX alone and vehicles controls 
[42]. Following debulking and induction of apoptosis of IP tumors with the 3-drug 
micelles, secondary micelles with a near-infrared (NIR) fluorescence probe, DiR, was 
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systemically administered to visualize and help remove residual tumors (Fig. 1) [59]. 
Here the secondary micelles were conjugated with a peptide having high affinity for 
apoptotic tissues (externalized phosphatidylserine) so that the secondary micelles could 
specifically visualize apoptotic tumors [59]. A similar approach was used for systemic 




Figure 1. Schematic illustration of two-step strategy for neoadjuvant therapy, apoptosis-
targeted optical imaging and intraoperative surgical guidance, enabled by a tandem of 
PEG-b-PCL micelles. (Reprinted from Cho, H. and Kwon, G.S., PLos One, 9,e89968, 
2014, per Creative Commons Attribution (CC BY) license.)  
 
While the particle systems in the above examples are intended for local drug 
delivery, they also provide a useful tool for lymphatic or systemic drug delivery. Particles 
administrated in the peritoneal cavity are drained into lymphatic circulation (Fig. 2) [48, 
62]. Within the lymphatic system, particles smaller than 50 nm pass through lymph nodes 
and reach systemic circulation via thoracic lymph ducts [62]. Kohane et al reported that 
even larger PLGA nanoparticles (265 nm) entered systemic circulation from the 
peritoneal cavity in less than 2 days, ending up in the spleen and the liver [40]. On the 
other hand, larger particles (>500 nm) are trapped in lymph nodes. Therefore, depending 
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on the particle size, nanoparticles can serve as a sustained systemic delivery system or for 
targeting cancer cells spreading via lymphatics.  
Conversely, microparticles (1-100 µm) are retained longer in the peritoneal cavity 
and, thus, have a greater potential to enhance local availability of a drug in the peritoneal 
cavity and attenuate systemic drug absorption than nanoparticles [48, 49] (Fig. 2). 
However, the long-term residence of microparticles in the peritoneal cavity can cause 
inflammatory tissue responses and peritoneal adhesions [40], which may offset the 
benefits of the localized medicine. For this reason, a combination of nanoparticles and 
hydrogels was proposed as an alternative option. Here, nanoparticles served as a 
sustained drug delivery system and hydrogels prevented premature clearance of 
nanoparticles from the peritoneal cavity [22]. Additionally, the hydrogel prevented the 








Figure 2. A model of kinetic processes during IP administration of nano- or 
microparticles. Nanoparticles are drained through the lymphatic system, reaching 
systemic circulation or trapped in the lymph nodes depending on the size. Microparticles 
tend to stay in the peritoneal cavity. Free drug released from particles are absorbed 
directly to IP tissues or systemic circulation. Consequently, microparticles can maintain a 
higher drug concentration in the peritoneal cavity than nanoparticles, whereas 
nanoparticles yield a higher rate and extent of systemic absorption than microparticles. 
(Modified from Tsai, M. et al., Pharm. Res., 24, 1691, 2007.) 
 
1.3.3 Implantable Depots 
Chitosan-phospholipid implantable formulations have been developed for 
sustained and localized delivery of taxane compounds to ovarian tumors in the peritoneal 
cavity [63-65]. The films were composed of chitosan and egg phosphatidylcholine (ePC) 
(Chitosan-ePC film) blended with PLA-b-PEG [66], PLA-b-PEG/PLA [67], or PLGA 
nanoparticles [68] containing PTX.  PTX release from the nanoparticle/chitosan-ePC 
films was evaluated in lysozyme-containing PBS [66], cell culture medium [68], or 
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release as the chitosan-ePC matrix swelled and degraded by lysozyme [66-68]. Animals 
implanted with chitosan-ePC films IP showed no signs of fibrous encapsulation or 
inflammation around the implant area over 2-4 weeks, indicating good biocompatibility 
of the implants [68]. The maximum tolerable dose (MTD) of PTX was 280 mg/kg/week 
when delivered with the nanoparticle/chitosan-ePC film, much higher than Taxol with the 
MTD of 20 mg/kg/week [64]. The PTX/nanoparticle/chitosan-ePC film significantly 
enhanced the anti-tumor efficacy as compared to Taxol at total dose of 60 mg/kg [64, 65]. 
It is noticeable that continuous sustained delivery of PTX by PTX/nanoparticle/chitosan-
ePC film (60 mg/kg) was superior to intermittent Taxol administration (20 mg/kg q7d  3 
schedule) at an equivalent dose and administration route (IP) in suppressing tumor 
growth and extending animal survival [65]. Moreover, intermittent Taxol administration 
resulted in a significant increase of tumor proliferation indices as compared with non-
treated controls, which indicates potential repopulation of tumors during treatment-free 
intervals [65]. In contrast, PTX/nanoparticle/chitosan-ePC film is thought to increase 
tumor responsiveness to the treatment by continuously exposing the tumors to high 
concentration of PTX by localizing the drug source in the peritoneal cavity [65]. In 
addition, PTX/nanoparticle/chitosan-ePC film did not induce the expression of multidrug 
resistance gene (MDR1) in-vivo, whereas intermittent Taxol administration caused 
significant MDR1 expression [69]. These results demonstrate the benefits of local 




1.3.4 Injectable Hydrogels 
The implantable films are an effective way of localizing chemotherapy in the 
peritoneal cavity, but the fact that it requires surgical implantation poses challenges in 
administration and patient compliance [70]. Therefore, the implantable film was replaced 
with an injectable depot (PoLigel), composed of a water-soluble chitosan derivative, ePC, 
and a fatty acid analog [70]. This mixture formed a gel at physiological temperature via 
hydrophobic interaction between water-soluble chitosan and acyl chains of ePC, 
reinforced by their interactions with a fatty acid analog [70]. Biocompatibility of the 
PoLigel depended on the fatty acid analog–lauric aldehyde was better tolerated than 
lauric chloride when injected subcutaneously in mice and observed over 4 weeks [71]. 
PoLigel was used for sustained and localized delivery of DTX to murine models of 
SKOV3 ovarian cancer [63, 72].  DTX loaded in PoLigel (DTX/PoLigel) showed 
constant release kinetics over 2 weeks with a minimal initial burst release in 0.01M PBS 
(pH 7.4) containing lysozyme and albumin [63]. DTX/PoLigel IP administrated to mice 
maintained constant DTX levels in plasma and peritoneal tissues over 2 weeks without 
causing significant toxicity or inflammation [63]. Tumor burden was reduced by >70% in 
DTX/PoLigel-treated group as compared with saline control [63]. Similar to the 
PTX/nanoparticle/chitosan-ePC film [65], DTX/PoLigel achieved a greater anti-tumor 
effect than intermittent Taxol injections, which was partly attributed to antiangiogenic 
effect of local DTX, continuously released by PoLigel [73]. In addition to local tumors, 
the IP administrated DTX/PoLigel was capable of delivering DTX to subcutaneous 
tumors distant from the peritoneal cavity [72].  This result demonstrates that IP sustained 
14 
 
and localized delivery platform can treat not only local tumors but also metastasis distal 
to the site of administration via the systemically absorbed drug. The PoLigel was also 
used for co-delivery of DTX and cepharanthine, where the latter inhibited multidrug 
resistance (MDR) due to drug efflux transporters and helped manage refractory ovarian 
cancer with the MDR phenotype [74]. 
Another type of injectable gel used for IP chemotherapy is a thermosensitive 
hydrogel based on PLGA-b-PEG-b-PLGA tri-block copolymers [75]. These polymers are 
soluble in water, form a free-flowing solution at low temperature (e.g., 4°C), but 
spontaneously gels at body temperature to create a water-insoluble gel called ReGel® [75]. 
ReGel® (23w/w%) injected subcutaneously into rats maintained the gel structure for 2 
weeks but degraded into a viscous liquid and gradually resorbed in the next 2 weeks. The 
hydrophobic segments (PLGA) formed hydrophobic regions in the gel, in which poorly 
water-soluble drugs could be encapsulated. ReGel® loaded with PTX (OncoGel™) 
released ~40% of the loaded PTX in the first 10 days and continuously released the 
remaining payload in the next 40 days. In subcutaneous injection and the FDA Modified 
Biocompatibility Tests, ReGel caused no signs of inflammation and significant toxicities, 
confirming its biocompatibility [75]. OncoGel has been evaluated in local therapy of 
solid tumors through preclinical and clinical studies and considered a promising adjuvant 
therapy for ovarian cancer [76]. ReGel® was recently evaluated as a carrier of a three-
drug combination (PTX and two protein inhibitors) for IP chemotherapy [77]. The three-
drug loaded ReGel (Triogel) IP injected as a free-flowing solution formed a depot at body 
temperature and released drugs at an equal rate according to gel erosion. The IP 
administered Triogel showed greater antitumor efficacy and lower systemic toxicity than 
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IP or IV administrated PEG-b-PLA micelles with the same payloads in ES-2 ovarian 
cancer xengraft model [77]. These results demonstrated the potential of Triogel as a 
multi-drug carrier for IP chemotherapy of ovarian cancer.  
While the PoLigel or ReGel form gels through non-covalent interactions between 
polymer chains, polymers with functional groups that can react in-situ and form covalent 
crosslinking to make hydrogels are also used for IP drug delivery [78]. The HA 
derivatives that formed in-situ hydrogels via hydrazone bond (Section 2.2.1 ) were 
evaluated for the prevention of post-surgical adhesion as a physical adhesion barrier 
and/or drug carrier, showing excellent biocompatibility in the peritoneal cavity and 
effectiveness in adhesion prevention [22, 34, 79, 80]. Accordingly, the in-situ 
crosslinkable HA hydrogels have also been evaluated as an IP drug delivery system for 
local therapy of cancers in the peritoneal cavity [36, 81].  
 
1.4 Challenges in IP Chemotherapy 
The above examples illustrate that various drug delivery systems deliver standard 
anti-cancer drugs to the peritoneal cavity and help manage peritoneal malignancies by 
providing sustained drug release and maintaining high local drug concentration. However, 
several challenges remain to be addressed before IP chemotherapy becomes a standard 




1.4.1 Drug Release in Peritoneal Environment 
The volume of peritoneal fluid in a healthy adult is about 50 mL with a turnover 
rate of 4-5 mL/h, whereas blood volume is ~5 L [82]. The protein content of peritoneal 
fluid is 25% of that in the blood [83]. Although malignancies may raise the protein level 
and accelerate the turnover in the ascites, the relatively small volume of the peritoneal 
fluid poses challenges to the IP delivery of poorly water-soluble drugs. Our previous 
effort to deliver PTX with HA-based hydrogel provides an example of such a challenge 
[36]. Here, PTX was mixed in HA hydrogel precursor solutions in the form of Taxol or 
concentrated DMSO solution and administered IP to tumor-bearing mice so that the 
precursors could form a hydrogel in-situ [36]. Upon dilution in the gel precursor solutions, 
the concentrated PTX/DMSO solution started to form micrometer-scale precipitates 
(PPTs), whereas Taxol maintained the micelle size (14 nm) [36]. The large particle size 
of the former and HA hydrogel helped maintain PTX in the peritoneal cavity over 2 
weeks. However, the prolonged retention of PPT-hydrogel did not translate to an 
improved anti-tumor effect, due to the large size of PPTs and, thus, limited dissolution of 
PTX [36]. This result indicates that hydrogel as a delivery medium helps localize drug in 
the peritoneal cavity but does not prevent precipitation of poorly water-soluble drug, 
limiting its availability to the local tumors.  
A potential solution to this problem may be to reduce the particle size to facilitate 
drug dissolution; however, it should not be as small as Taxol micelles as they are not 
retained in the hydrogel [36]. Therefore, the challenge is to produce drug particles with 
an optimal size, large enough to remain in the gel but small enough to allow continuous 
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and unhindered drug dissolution. There are several methods to produce drug particles in a 
specific size range [84]. For example, nanocrystallization is a technique to produce 
crystalline particles of poorly water-soluble drugs in the nanometer range (i.e., NCs). Due 
to the size and, thus, the high surface area to volume ratio, NCs can increase the 
dissolution rate of drug particles [85]. The unique advantage of NCs is that they are 
mainly composed of drug molecules and create little concern for the safety of excipients 
[86]. A minimal amount of surface stabilizers are however needed to prevent aggregation 
of NCs during their lifetime [87]. For example, ionic surfactants such as sodium cholate, 
sodium deoxycholate, and sodium lauryl sulfate are used to stabilize NCs via electrostatic 
repulsion. Alternatively, NCs are stabilized with amphiphilic polymers that establish a 
steric barrier against aggregation [86]. Another strategy is to use proteins as stabilizers 
[88]. Serum proteins, such as human serum albumin (HSA), can serve as a stabilizer due 
to their ability to adsorb onto hydrophobic surfaces and therefore provides steric 
hindrance to NC aggregation and growth [89, 90]. Moreover, serum proteins can interact 
with cell membrane to facilitate cellular uptake of anticancer drugs in tumors [91]. We 
have recently used PTX NCs stabilized with HSA for IP delivery with hydrogels (Fig. 3) 
and observed that the NC-hydrogel hybrid system had a superior anti-tumor activity than 






Figure 3. Schematic illustration of an injectable depot system, composed of an in-situ 
crosslinkable hydrogel and albumin-stabilized PTX NCs. 
 
1.4.2 Tumor Specificity and Penetration  
Reduced blood flow, increased interstitial fluid pressure, and high collagen 
density interfere with drug transport into solid tumors [92]. In addition, tumor hyaluronan 
[93] and stromal cells [94] in the tumor extracellular matrix aggravate the difficulty in 
drug penetration into tumors. While the tumor penetration is a general issue in 
chemotherapy of solid tumors [95], IP delivery faces a greater challenge than IV or 
intratumoral administrations in tumor penetration because IP administrated drugs mostly 
approach the tumor tissue from the periphery rather than the interior of the tumors (Fig. 
4). In-vitro studies using multicellular layers [96-99] and tumor spheroids [100, 101] 
have shown that limited drug penetration results in constant tumor exposure to a sub-
optimal level of drug, making an important mechanism for tumor resistance against 
chemotherapy. An approach to address this challenge is to loosen up the tumor matrix 
prior to chemotherapy to alleviate the drug penetration barrier [102, 103]. This strategy 
involved two-step chemotherapy with an interval, where the first treatment with pro-







the subsequent dose to reach the interior of the tumors. This study provided a proof of 
concept for the development of TPM for IP delivery of anticancer drugs or siRNA to 
peritoneal malignances (Section 3.2) [49, 57]. Manipulating tumor microenvironment is 
another way of improving delivery and intratumoral distribution of a drug or a 
nanoparticulate drug delivery system [104]. For example, local mild hyperthermia was 
applied to tumors to improve vasculature permeability, perfusion, and interstitial fluid 
flow [105]. Local hyperthermia at 41°C increased tumor vasculature permeability and 
allowed liposomes (~85 nm) to extravasate into the interstitial space (Fig. 5) [105]. This 
effect may explain the increasing popularity and positive clinical outcomes of IP 
chemotherapy combined with hyperthermia (hyperthermic intraperitoneal chemotherapy, 
HIPEC) [106-113]. Recently, several new approaches have been proposed to improve 
drug delivery to the interior of solid tumors [114, 115]. These approaches facilitate drug 
penetration into tumors by enhancing interactions between drug carriers and tumor 
stroma [116], preventing intracellular sequestration of a drug [117], or addressing 
hypoxic region of tumors prior to standard chemotherapy [118]. Although these studies 
have not been presented in the context of IP chemotherapy, it is worthwhile to explore 






Figure 4. Schematic illustration of poor penetration of IP administered drug. Drug 
approaching tumors from the peritoneal cavity has a limited depth of penetration, which 















Figure 5. (a) Liposome (red) extravasation through tumor vasculature (green) with or 
without mild hyperthermia for 1 h. (b) Quantification of liposome extravasation through 
tumor vasculature in 4 tumor models under local mild hyperthermia at 41 °C for 1 h. NEF, 
normalized extravascular fluorescence. Bar, 200 μm. Reprinted with permission from Li, 
L., Koning, G.A., et al. J. Control. Release, 130-137, Copyright  2013 Elsevier.)  
 
1.4.3 Tissue Responses to Carrier Materials 
1.4.3.1 Effects of Carrier Materials on Peritoneal Tissues 
As mentioned in section 2.1, careful selection of biomaterials as a drug carrier is 
particularly important for IP application because of the high sensitivity of the peritoneal 
cavity to foreign insults. Biomaterials generally considered biocompatible or wildly used 
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in other biomedical applications have caused inflammatory responses and peritoneal 
adhesion upon IP application. For example, PLGA microparticles (5 µm) induced 
adhesions 2 weeks after IP injection in mice [40]. This problem worsened with increasing 
molecular weight of the polymer [40]. A photo-crosslinkable chitosan derivative, which 
showed no attractive interactions or proliferative effect on mesothelial cells and 
macrophages in-vitro, caused extensive and persistent peritoneal adhesions in animals 
receiving it as a hydrogel in the peritoneal cavity [20]. It was later learned that the parent 
chitosan had the same effect in-vivo [20]. Both chitosans had significant pro-
inflammatory properties, which might have been tolerated in other locations but not in the 
peritoneal cavity. 
 
1.4.3.2 Effects of Carrier Materials on Tumors 
Drug carriers, once they are proven biocompatible, are often used under an 
assumption that they have no other roles than delivering the payload to the body. Our 
recent studies suggest otherwise. We have delivered platinum into the peritoneal cavity 
using HA nanoparticles and hydrogels IP in mice for local chemotherapy of ovarian 
cancer. We find that they do not show a greater anti-tumor efficacy than platinum 
solution but rather cause a slight increase in tumor burdens at later time points, which 
suggests a potential involvement of empty carriers and degradation products in the 
growth of residual tumors. This hypothesis is not groundless, given various biological 
roles of HA. HA is an indispensable extracellular matrix macromolecule for cell 
migration, differentiation and proliferation [119]. Endogenous HA is implicated in the 
invasion and growth of several tumor cells [119-122]. CD44, a well-known receptor of 
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HA, is found at the surface of various tumor cells and positively correlated with poor 
prognosis of ovarian cancer patients [123]. HA concentration in tumor stroma is 
considered an essential indicator of tumor aggressiveness and overall survival [124, 125]. 
However, the role of exogenous HA in tumor invasion and growth remains controversial. 
Picaud et al reported that HA-carboxymethyl cellulose (CMC) membrane had no effect 
on the proliferation of tumor cells in-vitro and in-vivo [126]. Similarly, HA-based anti-
adhesion membrane was found to have no influence on metastasis of colon cancer in a 
human xenograft/nude mouse model [127]. On the other hand, Tan et al reported that HA 
solution promoted proliferation and motility of colorectal tumor cell lines and increased 
peritoneal tumor load as compared with non-treated control group, confirming its positive 
role on metastatic potential of colorectal tumors [128]. Although the exact effect of HA-
based biomaterials on IP tumors and its role remain to be investigated, the mixed results 
beg a question – if the drug carrier is indeed biologically inert and does no harm after 
when it remains in the body after complete exhaustion of the payload. This means that in 
designing a new drug carrier one should consider not only the biocompatibility of the 
material but also its biological effects on residual tumors, which may not be readily 
predicted from routine toxicity testing. 
 
1.5 Conclusion 
The premise of IP chemotherapy in the treatment of malignant diseases confined 
in the peritoneal cavity lies in the theoretical potential for increased exposure of the 
tumors to anti-cancer drugs and improved toxicity to local tumors [12]. Although the 
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proof of concept has been demonstrated in several clinical trials, current practice of IP 
chemotherapy leaves plenty of room for improvement in delivery methods. Solutions, 
micro- or nanoparticles, implantable depots, and in-situ crosslinkable hydrogels have 
been evaluated in the context of IP chemotherapy, achieving varying levels of success in 
preclinical studies. Due to the unique biological environment of the peritoneal cavity, 
several challenges remain to be overcome before the IP drug delivery systems can benefit 
patients to the full potential. Despite the needs and gravity of the challenges, there are 
surprisingly few players in the field of IP drug delivery systems. It means that this is a 
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CHAPTER 2. DEVELOPMENT AND CHARACTERIZATION OF NANOPARTICLE 
DEPOT FOR INTRAPERITONEAL CHEMOTHERAPY2 
2.1 Introduction 
The potential advantages of IP chemotherapy have been discussed thoroughly. 
However, frequently mentioned problems are the complications related to IP infusion, 
including abdominal pain, intolerance to a high level of drug, and discomfort related to 
the catheter implantation [1]. We speculate that these problems mainly stem from the 
difficulty in controlling drug release. Small molecule drugs such as paclitaxel (PTX) or 
docetaxel were cleared from the peritoneal cavity in less than one day [2-4]. The short IP 
retention time requires frequent or continuous dosing, necessitating the use of large 
volume of treatment and indwelling catheters. For IP chemotherapy to provide the 
anticipated benefits, it is critical that the formulation control the drug release and avoid 
burst initial release, followed by immediate absorption to the systemic circulation.  
Considering this need, we previously used a hyaluronic acid (HA)-based hydrogel 
(gel) as a carrier of PTX provided in the form of micrometer-scale precipitates (PPT) to 
improve their IP retention and control the drug release [5]. The gel remained in the 
peritoneal cavity and maintained the high level of local PTX concentration for 2 weeks. 
                                                 
2 The content of this chapter is adapted with permission from Sara A. Abouelmagd, Bo Sun, 
Alice C. Chang, et al., Release kinetics study of poorly water-soluble drugs from nanoparticles: Are we 
doing it right? Mol. Pharm. 2015, 12(3), p 997-1003. Copyright (2015) American Chemical Society.  
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However, when tested in a murine model of IP SKOV-3 human ovarian cancer, the PPT-
gel had no more benefit than Taxol-gel, which did not retain PTX as well as PPT-gel did. 
One of the possible explanations was that the dissolution of PPT was too slow to provide 
an effective local drug concentration.  
In the present study, we aim to overcome this challenge by designing a drug 
delivery system that can localize PTX in the peritoneal cavity and provide sustained, yet 
uninterrupted PTX release. PTX is used as a model drug because it is a first-line therapy 
of ovarian cancer for both intravenous and intraperitoneal administration [6-9]. Besides, 
PTX is a well-known poorly water-soluble drug, previously found to be challenging to 
control the release in the peritoneal cavity with a limited amount of fluid.  
PTX is formulated as nanocrystals (NCs), crystalline particles of poorly soluble 
drugs in the nanometer range [10]. Due to the small size of NC and thus, the high surface 
area to volume ratio, NC can increase the dissolution rate of drug particles [11]. 
Typically, NCs are produced by breaking down large particles (“top-down”) or 
crystallizing from drug solutions (“bottom-up”) of the drug itself with an optional aid 
with surfactants or polymeric stabilizers on the surface [10, 12]. Here, we produce PNC 
by nonsolvent and temperature-induced crystallization [13] and evaluate its in-vitro 
dissolution in comparison with PPT.   
PNCs are then embedded in HA gel. IP-administered small molecule drugs could 
be cleared out from peritoneal cavity in a few hours which compromised the 
effectiveness of local chemotherapy [14-16]. In situ forming gel has been developed as a 
standalone drug delivery system to handle the short residence time of chemotherapeutic 
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agents [5, 17-21]. HA gel is degradable in-vivo by prevalent hyaluronidase and highly 
biocompatible [22-25]. In this study, we anticipate that HA gel will provide a local 
reservoir of PNC and prolong the retention of PTX in the peritoneal cavity to provide 
sustained local delivery of chemotherapy to ovarian tumors.  
In order to predict PTX dissolution within the peritoneal cavity, it is necessary to 
develop a dissolution method that accounts for biological and physicochemical factors 
relevant to in-vivo conditions. Several attempts have been made to estimate the PTX 
release profiles from gel formulations in conditions mimicking the peritoneal cavity with 
a limited fluid volume and amphiphilic components.  
 
2.2 Materials and Methods 
2.2.1 Materials 
Hyaluronic acid (HA, 20 kDa and 500 kDa) was purchased from Lifecore 
Biomedical, LLC (Chaska, MN, USA). Paclitaxel (PTX) was a gift of Samyang Genex 
Corp (Seoul, Korea). Carbamazepine was purchased from Enzo life sciences (Plymouth 
Meeting, PA, USA). Cremophor ELP was a gift from BASF (New York, NY, USA). 
Carboxyl methylcellulose sodium (CMC, 250 kDa) was purchased from Sigma-Aldrich. 
Cell culture medium and supplements were purchased from Invitrogen (Carlsbad, CA, 




2.2.2 Preparation and Characterization of PTX Nanocrystals (PNC) 
PTX nanocrystals (PNC) were prepared according to the published method [13]. 
Briefly, 4 mg/mL PTX/ethanol solution was added to 20 mL of deionized (DI) water and 
stirred at 42 rcf for 10 min in a round-bottom flask immerged in a sonication bath filled 
with ice water. The formed PNC was captured on a 100 nm polycarbonate membrane and 
resuspended in DI water. Taxol and PTX precipitates (PPT) were prepared as described 
previously [5]. Taxol was prepared by dluting “Taxol concentrate” (6 mg PTX dissolved 
in 1 mL of 1:1 mixture of Cremophor ELP and ethanol). PPT was prepared by the 
addition of 30 mg/mL of PTX-dimethyl sulfoxide (DMSO) solution to DI water without 
low temperature, vigorous stirring and sonication. Particle size of PNC was measured 
with a Zetasizer Nano-ZS90 (Malvern instruments, Westborough, MA, USA). The zeta 
potential of PNC and PPT were measured with a Zeta sizer Nano-ZS90 in 1 mM 
phosphate buffer (pH 7.4). The morphology of lyophilized PNC and PPT was visualized 
with a FEI Nova nanoSEM field emission scanning electron microscopy (Hillsboro, OR, 
USA). Freeze dried PNC or PPT was sputter-coated with platinum for 1 min and 
observed with a high resolution through-the-lens detector under 5kV accelerating voltage 
and spot size 3. PPT suspended in DI water was observed with Axio Imager 2 microscope 
with polarized light (Carl Zeiss Microscopy GmbH, Germany). X-ray powder diffraction 
(XPRD) patterns of lyophilized PNC and PPT were obtained on a Siemens D5000 X-ray 
diffractometer with a Cu Kα radiation source (40kV, 40 mA). All the measurements were 
conducted at room temperature over an angle (2θ) range of 5-40° with a step size of 0.02° 
and a scan rate of 4°/min.  
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2.2.3 Synthesis of Gel Precursors (HA-ADH, HA-CHO, CMC-CHO) 
In-situ crosslinkable HA derivatives, HA-adipic acid dihydrazide (HA-ADH) and 
HA-aldehyde (HA-CHO), and a crosslinkable HA gel were prepared as described 
previously [5, 26]. Briefly, HA-ADH was synthesized by conjugating adipic dihydrazide 
to carboxyl groups in HA which was catalyzed by 1-ethyl-3-carbodiimide (EDC) and 1-
hydroxybenzotriazole (HOBt) at pH 6.8 and room temperature.  HA-CHO was produced 
by oxidizing HA with sodium periodate. HA-ADH and HA-CHO were purified by 
dialysis, freeze dried and stored at 4°C until use. Carboxyl methylcellulose-aldehyde 
(CMC-CHO) was synthesized in the same approach as HA-CHO.  
 
2.2.4 Synthesis of Hydrophobically Modified Gel Precursor (EtCA-CMC-CHO)  
2.2.4.1 Synthesis of 5β-cholanic Acid Methyl Ester (MeCA) (Scheme 1) 
500 mg of 5β-cholanic acid (CA) (1.4 mmol) was dissolved in 50 mL of methanol 
with 180 µL concentrated hydrochloride acid (4.9 µmol) at 60°C. The solution was 
stirred for 6h under reflux. The solution was cooled to room temperature and added 
dropwise into cold deionized water to obtain precipitates, which were further filtrated and 
washed with cold methanol for 3 times and cold deionized water for 3 times. The product 
was dried under vacuum at room temperature to obtain MeCA.  
 
2.2.4.2 Synthesis of Aminoethyl 5β-cholanoamide (EtCA) (Scheme 1) 
450 mg of MeCA (1.2 mmol) was dissolved in 8 mL of ethylene diamine (119.6 
mmol) under stirring and reflux for 6h at 130 °C. The solution was cooled to room 
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temperature and added dropwise into cold deionized water to obtain precipitates, which 
were further filtrated and washed with cold deionized water for 5 times. The final product 
(EtCA) was dried under vacuum at room temperature and its chemical structure was 




Scheme 1. Synthesis scheme of aminoethyl 5β-cholanoamide.  
 
2.2.4.3 Synthesis of EtCA-CMC-CHO Conjugate (Scheme 2) 
41 mg of CMC-CHO (100 µmol) was dissolved in 37 mL of methanol/water 
(2v/1v) containing 20.6 mg of N, N’-Dicyclohexylcarbodiimide (DCC, 100 µmol) and 
11.5 mg of N-Hydroxysuccinimide (NHS, 100 µmol) under stirring at room temperature 
for 1h. After 4 or 12 mg of EtCA (10 or 30 µmol) in 1 mL of methanol was slowly added, 
the reaction mixture was stirred for 12h. The resulting solution was dialyzed against 
methanol/water (2v/1v) for 2 days and deionized water for another 2 days. EtCA0.1 or 0.3-






Scheme 2. Synthesis scheme of EtCA-CMC-CHO conjugate. 
 
2.2.5 Preparation of Gel formulations 
Gels were prepared by suspending PNC or PPT in solutions of gel precursors (one 
ADH derivative and one CHO derivative) in phosphate buffer saline (PBS, pH 7.4) and 
extruding them through a common outlet using a double-barreled syringe. HA gel was 
made of HA-ADH and HA-CHO; HA-CMC gel was made of HA-ADH and CMC-CHO. 
The polymer concentration in gel was 40 mg/mL.  When EtCA0.1-CMC-CHO was used, 
37.5% (w/w) of HA-CHO was replaced with EtCA0.1-CMC-CHO. HA-EtCA0.1-CMC gel 




2.2.6 Evaluation of Gel Precursors and Crosslinked Gels 
2.2.6.1 Hydrophilicity of Gel Precursors 
Contact angle is defined as the angle formed by the intersection of the liquid-solid 
interface and the liquid-vapor interface [27]. The larger a contact angle is, the more 
hydrophobic the surface is. The hydrophilicity of a specific material can be evaluated by 
measuring the contact angle of water droplet placed on the thin film made of the material.  
Four gel precursors, HA-CHO, CMC-CHO and EtCA0.1 or 0.3-CMC-CHO, were 
dissolved in deionized water at 10 mg/mL. The solutions were casted on glass slides 
respectively and dried at ambient temperature for 12h to form thin films. The contact 
angle of water droplet on each polymeric film was measured with a contact angle 
goniometer.  
 
2.2.6.2 Toxicity of EtCA and EtCA-CMC-CHO  
Toxicity of CA, MeCA, EtCA and EtCA0.1-CMC-CHO were studied with 
NIH/3T3 fibroblast cells (ATCC). NIH/3T3 cells were maintained in Dulbecco's 
Modified Eagle's Medium (DMEM) medium supplemented with 10% bovine calf serum 
(BCS) and 1% penicillin-streptomycin. Cells were plated in a 96-well plate at a density of 
8,000 cells per well with 0.2 mL of complete medium. After 24h incubation, CA, MeCA, 
EtCA (in methanol) or EtCA0.1-CMC-CHO (in PBS) was added to each well at varied 
concentrations and incubated with cells for 2 days. A control group was treated with an 
equal volume of methanol or PBS. The cell viability was evaluated with the MTT (3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. The absorbance of the 
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solubilized formazan was measured with a SpectraMax M3 microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) at a wavelength of 562 nm. The measured absorbance 
was normalized to the absorbance of the control group.   
 
2.2.6.3 Toxicity of Gels  
Toxicity of gels was evaluated with NIH/3T3 cells using Transwells. Cells were 
plated in a 12-well plate at a density of 17,500 cells per wells with 1.5 mL DMEM 
complete medium (cell density equal to 5,000 cells per well in 96-well plate). CMC-
CHO, HA-CMC gel or HA-EtCA0.1-CMC gel was added to the apical side of a Transwell 
polycarbonate membrane insert (pore size = 0.4 µm), placed in the 12-well plate, and 
incubated with cells for 2 days. Cell viability was evaluated with MTT assay as described 
above.  
 
2.2.7 PTX Solubility and Stability in Various Media  
2.2.7.1 PTX Solubility in PBS, PBS Containing Serum, or PBS Containing Tween 80 
PTX solubility in PBS, PBS containing 0.2 v/v% Tween 80 (Tween/PBS), and 
PBS containing 50 v/v% FBS (50-FBS/PBS) were determined by incubating excess PTX 
(0.6 – 2.4 mg) in 1 mL of each medium at 37 °C for 7 or 24 h with agitation. Samples 
were centrifuged at 9300 rcf for 20 min to separate a supernatant. PTX dissolved in PBS 
and Tween/PBS was analyzed with HPLC as described in Section 2.2.4. PTX dissolved 
in 50-FBS/PBS was first extracted with ethyl acetate and reconstituted in the HPLC 
mobile phase prior to HPLC analysis.  
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2.2.7.2 PTX Stability in PBS Containing Tween 80 or PBS Containing Serum 
The stability of a drug was an important issue if it would be tested or delivered for 
an extended period of time. PTX stability was first tested in a fully dissolved state (PTX 
concentration below the solubility limit). 1.5 µg/mL of PTX solution in Tween/PBS was 
prepared by diluting 10 mg/mL PTX-DMSO solution with Tween/PBS (final DMSO 
concentration: 0.015%). The solution was divided into several 1 mL aliquots, and the 
initial PTX concentration was determined with 7 of them. The remaining aliquots were 
incubated at 37°C, and 3 aliquots were taken at predetermined time points and kept at -
80°C until HPLC analysis. The frozen samples were thawed and filtered through 0.45 µm 
filters for HPLC analysis. The concentration of intact PTX at each time point was divided 
by the original PTX concentration (1.5 µg/mL) and expressed as the percentage of 
original PTX.  
PTX stability in 50-FBS/PBS was tested in its solid form of PNC and PPT at a 
concentration of 100 µg/mL (above solubility limit) and compared to that of Taxol. These 
PTX formulations were incubated in 50-FBS/PBS at 37 °C for 10 days. PTX remained in 
the suspensions was extracted with ethyl acetate and analyzed with HPLC.  
 
2.2.8 Dissolution Kinetics of PNC  
PTX dissolution was first tested with the dialysis method. Three milliliters of PBS 
containing 200 µg PNC was injected into a dialysis cassette (MWCO= 3.5 kDa). The 
cassette was placed in 200 mL PBS. Therefore, the initial PTX concentrations in cassette 
and in the system were 66.7 µg/mL and 1 µg/mL, respectively.  The cassette was 
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incubated in PBS at 37 °C on an orbital shaker for 10 days. At predetermined time point, 
5 mL of the release medium was sampled and replaced with 5 mL of fresh PBS. PTX in 
the release medium was extracted with ethyl acetate and analyzed as described in Section 
2.2.4. At the completion of this study, dialysis cassettes were rinsed with PBS to collect 
the remaining PTX. PTX leftover was analyzed in the same way as release samples.  
To determine how quickly PTX precipitated in PBS at 37 °C, PTX solution in 
PBS at a concentration of 20 µg/mL was prepared by diluting 1 mg/mL PTX stock 
solution in Tween/PBS with PBS (Tween80 concentration in the diluted solution was 
below the critical micelle concentration 0.0015%), aliquoted by 1 mL, and incubated at 
37°C with shaking. At predetermined time points, 3 aliquots were taken and centrifuged 
at 2095 rcf for 5 min. The supernatants were additionally centrifuged at 9300 rcf for 20 
min and filtered with 0.45 µm PVDF syringe filters and directly analyzed with HPLC.  
Dissolution kinetics of PPT and PNC was also tested in PBS containing 0.2% 
Tween 80 (PBST) following a method based on light scattering [28]. PPT suspension was 
prepared by diluting 30 mg/mL PTX in DMSO in PBS by 100 times. PNC suspension (1 
mg/mL) was pre-diluted in 0.2% PBST by 10 times. Final dilution was performed 
directly in a cuvette by adding 20 µL of pre-diluted PNC (equivalent to 2 µg of PTX) or 
6.7 or 20 µL of PPT suspension (equivalent to 2 or 6 µg of PTX) to 1 mL of 0.2% PBST. 
Their derived count rates were measured with a Zetasizer Nano-ZS90 from the time of 
final dilution. Each measurement was done for 3 runs at 3s with a 30-sec interval and an 




2.2.9 PTX Release Kinetics of HA Gel Formulations 
PTX release from gel formulations was studied in two ways: one in the sink 
condition (total drug concentration being less than one third of the saturation solubility 
[29]) and the other in a condition violating the sink condition to simulate the peritoneal 
environment which has limited fluid available for drug dissolution. PNC-gel and PPT-gel 
referred to PNC loaded in HA gel and PPT loaded in HA gel, respectively. 
 
2.2.9.1 In Tween/PBS under Sink Condition 
For the release kinetics study in the sink condition, 0.1 mL of PNC-gel or PPT-gel 
containing 22 µg PTX was formed as described above and placed in a tube containing 20 
mL of Tween/PBS (n=3). This condition made the initial PTX concentration in the 
release medium 1.1 µg/mL, one third of the PTX solubility in Tween/PBS (3.3 µg/mL) 
[30]. Thirty six identical samples were incubated at 37 °C on an orbital shaker. At 
predetermined time points, 3 samples per group were taken and centrifuged at 2095 rcf or 
10 min to separate the gels. The collected gels were freeze dried and incubated with 5 mL 
mixture of acetonitrile/water (50/50) (ACN/water) at room temperature for 24 h. The 
swollen gels were ground with a mortar and a pestle to release PTX into ACN/water. The 





2.2.9.2 In Tween/PBS under Non-Sink Condition 
For a non-sink condition, 0.3 mL of PNC-gel or PPT-gel containing 200 µg PTX 
was placed in a tube containing 20 mL of Tween/PBS (n=3). The initial PTX 
concentration in the release medium was therefore 10 µg/mL, 3 times higher than the 
PTX solubility in Tween/PBS [30]. All the samples were incubated at 37°C on an orbital 
shaker. At predetermined time points, 3 mL release medium were sampled and 
centrifuged at 9300 rcf for 10 min to separate a supernatant. Two milliliters of the 
supernatant was taken for HPLC analysis, and the remaining 1 mL was combined with 2 
mL of fresh Tween/PBS and returned to the sample tube for further incubation. At 
completion of the study, the remaining mass in the sample container was freeze-dried and 
reconstituted with 10 mL of acetonitrile to determine the PTX leftover. 
PTX release from HA-EtCA0.1-CMC gel was also tested in Tween/PBS under 
non-sink condition with minor differences. HA-EtCA0.1-CMC gel containing PPT was 
formed as described in Section 2.2.5 by replacing 37.5% (w/w) of HA-CHO with 
EtCA0.1-CMC-CHO. 0.3 mL of PPT-(HA-EtCA0.1-CMC) gel containing 200 µg of PPT 
was placed in 20 mL of Tween/PBS. All the samples were incubated at 37 °C on an 
orbital shaker. At predetermined time points, 5 mL release medium were sampled and 
centrifuged at 2095 rcf for 10 min to separate a supernatant. Two milliliters of the 
supernatant was taken for HPLC analysis, and the remaining 3 mL was combined with 2 
mL of fresh Tween/PBS and returned to the sample container for further incubation. At 
completion of this study, the remaining mass in the sample container was freeze-dried 
and reconstituted with 10 mL of acetonitrile to determine the PTX leftover.  
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2.2.9.3 In FBS/PBS or Tween/PBS containing Hyaluronidase under Non-Sink 
Condition 
Hyaluronidase, a prevalent enzyme in the body, was added in the release medium 
to simulate the degradation of HA gel in the peritoneal cavity. 0.3 mL of PNC-gel or 
PPT-gel containing 200 µg PTX was placed in 20 mL of 25 v/v% FBS (25-FBS/PBS) or 
Tween/PBS containing hyaluronidase (10 U/mL). The initial PTX concentration in the 
release medium was therefore 10 µg/mL. All the samples were incubated at 37°C on an 
orbital shaker. At predetermined time points, 5 mL release medium were sampled and 
centrifuged at 2095 rcf for 10 min to separate a supernatant. Two milliliters of the 
supernatant was taken for HPLC analysis, and the remaining 3 mL was combined with 2 
mL of fresh 25-FBS/PBS and returned to the sample container for further incubation. At 
the completion of the study, the remaining mass in the sample container was freeze-dried 
and reconstituted with 10 mL of acetonitrile to determine the PTX leftover.  
 
2.2.10 HPLC Analysis of PTX  
PTX in PBS or PTX in Tween/PBS solution was directly analyzed with HPLC 
after filtration with 0.45 µm PVDF syringe filter. PTX in PBS containing 50 or 25 v/v% 
FBS was extracted with ethyl acetate prior to HPLC analysis. Briefly, 1 mL of PTX 
solution in FBS medium with 10 µg of carbamazepine as an internal standard was mixed 
with 3 mL ethyl acetate and shaken on a rotating shaker for 40 min. The mixture was then 
centrifuged at 2095 rcf for 15 min to separate an organic layer, which was transferred to a 
new glass vial and dried under vacuum. The dried sample was resuspended in the HPLC 
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mobile phase, filtered through 0.45 µm syringe filter, and analyzed by HPLC. A 
calibration curve was drawn with PTX solutions in FBS medium in known 
concentrations, treated in the same manner as the sample solutions. PTX was analyzed 
with HPLC equipped with UV detector (1100 series, Agilent Technologies, Palo Alto, 
CA) and an Ascentis C18 column (25 cm × 4.6 mm, particle size 5 µm) (Supelco, St. 
Louis, MO, USA). The mobile phase was a mixture of acetonitrile and water (50:50) run 
in the isocratic mode at a flow rate of 1 mL/min. PTX was detected at 227 nm.  
 
2.3 Results and Discussions 
2.3.1 Characterization of PNC and PPT  
The properties of PNC and PPT are summarized in Table 1. PNC showed a rod-
shape with a length of 310 ± 86 nm and a width of 65 ± 10 nm under SEM (Fig. 6A). The 
average diameter of PNC measured by Dynamic Light Scattering (DLS) was 258.0 ± 
28.1 nm (average and standard deviation of 8 independently prepared batches) with 
polydispersity index values ranging from 0.045 to 0.223, which indicated mid-range 
polydispersity. On the contrary, PPT were needle-shaped crystals with a length of 11.5 ± 
2.2 µm and a width of 2.0 ± 0.4 µm (Fig. 6B). Polarized light microscopy detected 
clusters of PTX crystals, confirming the broad size distribution of PPT. Both PNC and 
PPT showed weakly negative charges (PNC: -5.51 ± 0.42 mV; PPT: -3.08 ± 0.98 mV) at 
pH 7.4. PNC and PPT exhibited sharp peaks typical of crystalline solids (Fig. 6C). The 






Figure 6. (A) Scanning electron micrograph of PNC. (B) Polarized light micrograph of 
PPT. (C) XPRD pattern of PNC and PPT.  
 
Table 1. Summary of PNC and PPT properties 
 PNC PPT 
Particle size Length1: 310 ± 86 nm; 
Width1: 65 ± 10 nm   
z-average2: 258 ± 28.1 nm 
Length3: 11.5 ± 2.2 µm;  
Width3: 2.0 ± 0.4 µm 
Zeta potential4 -5.51 ± 0.42 mV -3.08 ± 0.98 mV 
1Estimated by SEM; based on 50 measurements with ImageJ 
2Measured by a zeta sizer (DLS); average and standard deviation of 8 independently 
prepared batches 
3Estimated by light microscopy; based on 50 measurements with ImageJ 





2.3.2 Synthesis and Characterization of EtCA-CMC-CHO 
In an attempt to increase compatibility between PNC and the hydrogel carrier, 5β-
cholanic acid was introduced to one of the gel precursors. 5β-cholanic acid has been 
conjugated to HA as EtCA to make an amphiphilic HA conjugate that formed self-
assembly nanoparticles for cancer therapy in the literature [31]. The EtCA synthesis was 
adapted to produce EtCA-CMC-CHO. The chemical structure of EtCA was confirmed 
with 1H NMR as shown in Fig. 7. The characteristic peaks of EtCA appeared from the 
ethylene group (δ = 3.3 ppm [2H, –NHCH2–], δ = 2.7 ppm [2H,–CH2NH2]). EtCA0.1 or 0.3-
CMC-CHO was poorly soluble in water, which confirmed the conjugation of EtCA to 
CMC-CHO. However, due to the low solubility in D2O and CD3OD, the chemical 




Figure 7. 1H NMR spectrum of EtCA (300 MHz, CD3OD). δ=3.30 (m, 2H), 2.86 (m, 2H), 




2.3.2.1 Hydrophobicity of Gel Precursors 
Contact angles of water droplet on the thin films of different gel precursors were 
measured to compare their hydrophobicity. The contact angles of EtCA0.1-CMC-CHO 
and EtCA0.3-CMC-CHO were similar but much higher than those of HA-CHO or CMC-
CHO, indicating the hydrophobicity imparted by EtCA (Table 2). EtCA0.1-CMC-CHO 
was chosen for further studies and used as a partial replacement of HA-CHO, because it 
was easier to dissolve in water than EtCA0.3-CMC-CHO.  
Table 2. Contact angles of water droplet on gel precursor films.  




Contact angle ( ) 33.0±2.0 38.8±1.4 63.2±7.3 67.2±2.7 
 
2.3.2.2 Toxicity of EtCA and EtCA-CMC-CHO Conjugate  
Quite unexpectedly, EtCA showed high toxicity on NIH/3T3 cells at all tested 
concentrations (2-71 µg/mL) (Fig. 8A). CA or MeCA, precursors of EtCA, did not show 
comparable toxicity, which indicated that the toxicity came from ethylene diamine 
conjugation. Accordingly, EtCA0.1-CMC-CHO was toxic to NIH/3T3 cells at 
concentrations ≥ 100µg/mL (equivalent to EtCA 9 µg/mL or above with a theoretical 
EtCA content in EtCA0.1-CMC-CHO of 9.5%) (Fig. 8B and 8C). Toxicity of EtCA0.1-
CMC-CHO was further evaluated after gel formation. HA-EtCA0.1-CMC gel was placed 
on the apical side of the insert and immersed in the culture medium, letting degradants or 
molecules dissociated from the gel approach the cells through the pores of the membrane 
insert. After 2 days incubation, cells treated with HA-EtCA0.1-CMC gel (equivalent to 
67.5 µg/mL EtCA) were all dead (Table 3). CMC-CHO showed no toxicity on NIH/3T3 
cells, and cells treated with HA-CMC gel maintained about 72% cell viability. Due to the 
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significant toxicity, EtCA0.1-CMC-HA gel containing 1.7% w/w of EtCA was not further 
pursued in animal studies. Nevertheless, in-vitro release kinetics from PNC-loaded 
EtCA0.1-CMC-HA gel was studied to examine the effect of hydrophobic moiety in the gel 




Figure 8. Toxicity of EtCA and EtCA0.1-CMC-CHO.  
 
Table 3. Toxicity of gel precursors and gels with NIH/3T3 cells  






CHO in 0.2 mL 
PBS  
0.2 mL gel 
consisting of  4 
mg HA-ADH, 
2.5 mg HA-CHO 
and 1.5 mg 
CMC-CHO 
0.2 mL gel 
consisted of  
4mg HA-ADH, 
2.5 mg HA-CHO 
and 1.5 mg 
EtCA0.1-CMC-
CHO  
0.2 mL PBS  
Cell viability% # 106.4 ± 4.9 71.6 ± 3.2 0 100% 
* Each sample (0.2 mL total) was placed in the apical side of a Transwell and 
supplemented with 0.3 mL DMEM prior to placement in the 12-well plate containing 1.5 
mL medium and 17,500 cells. #: cell viability expressed as average ± standard deviation 













2.3.3 PTX Solubility and Stability in Various Media 
2.3.3.1 PTX Solubility in PBS, 50-FBS/PBS, or Tween/PBS 
Prior to testing PNC dissolution kinetics and PTX release kinetics from gel 
formulations, PTX solubility was evaluated in PBS, Tween/PBS, and 50-FBS/PBS after 
incubation at 37 °C for 7 or 24h. PTX solubility in PBS was measured at ~0.2 µg/mL 
with no specific trend according to the incubation time, although the values were variable 
due to the sensitivity limitation of HPLC (Fig. 9A). PTX solubility in Tween/PBS was 
measured to be 3.3 µg/mL irrespective of the incubation time (Fig. 9B). PTX solubility in 
50-FBS/PBS was measured at 35 µg/mL after 7h incubation at 37 °C, much higher than 
those in PBS or Tween/PBS, which confirmed the solubilizing effect of serum proteins 
(Fig. 9C). Notably, PTX concentration measured after 24h incubation was 25 µg/mL, 
28.6% lower than that after 7h.  This difference is attributable to the instability of PTX in 
serum, reported in our previous study [5] as well as in others. 38.5% of paclitaxel was 
hydrolyzed to 7-epitaxol in cell culture medium containing FBS within 10h [32] and 
35 % of paclitaxel would degrade in 24h at 37 °C in human plasma [33]. This indicates 
that, if PTX release kinetics studies are performed in serum-containing medium and the 
medium is not sampled and analyzed frequently, one may not recover 100% of PTX from 
the formulation due to the degradation of released PTX. On the other hand, PTX was 
relatively more stable in Tween/PBS as compared to 50-FBS/PBS, maintaining 94% of 
the initial concentration for 1 day (Fig. 9D). This means that, as long as the medium is 






Figure 9. PTX solubility in (A) PBS, (B) Tween/PBS, or (C) 50-FBS/PBS. Blue square: 
measured after 7h; red triangle: measured after 24h. (D) Stability of 1.5 µg/mL PTX in 
Tween/PBS at 37 °C.  
 
2.3.3.2 PNC Stability in PBS Containing Serum  
PTX stability in serum-containing medium improved when it was incubated as 
solid particles. PTX was least stable as Taxol and more stable as solid (PNC and PPT) in 
25-FBS/PBS (Fig. 10). Between PNC and PPT, the recovery of PNC was relatively low, 
likely due to the faster initial dissolution of PNC due to the small size. The improved 







Figure 10. Stability of PTX formulations (0.1 mg/mL) in 25-FBS/PBS for 10 days (n=6). 
*: p<0.05. 
 
2.3.4 Dissolution Kinetics of PNC and PPT  
2.3.4.1 Dissolution Kinetics of PNC and PPT with Dialysis Method 
PTX dissolution kinetics from PNC or PPT was evaluated using the dialysis 
method and PBS as a release medium. Here, the PNC equivalent to 200 µg PTX was 
suspended in 3 mL of PBS, put in a dialysis cassette, and incubated in 200 mL of PBS. 
Fig. 11A shows that PTX dissolution from the PNC was very slow, reaching less than 
10% cumulative release in 10 days. Given that the PTX concentration in the dialysis 
cassette was 66.7 µg/mL, far exceeding the solubility (0.2 µg/mL), and the dialysis 
membrane could delay PTX diffusion into the release medium, we suspected that PTX 
might have precipitated in the dialysis cassette. Indeed a significant fraction of PTX 
remained in the dialysis cassette after 10 days. To estimate how quickly PTX precipitated 
in a dialysis cassette, we prepared a 20 µg/mL PTX solution in PBS (<1/3 of the initial 
concentration in a dialysis cassette) and sampled the solution at different time points to 






















PTX in solution only to the solubility level (Fig. 11B). This result suggests that even 
though the small size of PNC had increased the dissolution rate of PTX, the dissolved 
PTX might have undergone reprecipitation in the dialysis cassette. In other words, PTX 
detected in the release medium did not necessarily reflect the dissolution of PNC but that 
of PTX precipitates entrapped in the cassette. Since only the dissolved PTX could pass 
the membrane and became diluted in the release medium, the PTX concentration in the 
release medium was <0.1 µg/mL, much below the solubility limit, at any time point (Fig. 
11C).  
Drug dissolution or release kinetics of a particulate formulation is typically 
studied by separating dissolution medium from the formulation by high speed 
centrifugation or a dialysis bag and measuring the drug concentration in the sampled 
medium. Neither is appropriate for estimating PTX dissolution from PNC or PPT: 
centrifugation does not completely separate small particles from the suspension and 
accelerates particle aggregation, and the dialysis method bears the risk of underestimating 
drug release/dissolution due to drug adsorption to the membrane and/or reprecipitation of 
dissolved drug in the bag [30].  
Given these challenges, we resorted to an in-situ analytical technique based on 
light scattering [28]. As expected, the derived count rate of PNC decreased from the 
initial value of 214.3 kcps to 22.0 kcps (count rate of PBST) in 10 min, indicating rapid 
dissolution of PNC in PBST. On the other hand, PPT showed an average count rate of 
23.0 kcps from the beginning and did not change for 4 min, likely due to the small 
number of PPT particles per volume and/or their instantaneous sedimentation. The count 
rate was not much different (26 kcps) even when the concentration of PPT suspension 
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was tripled (6 µg/mL, above the PTX solubility in 0.2% PBST) (Fig. 11D). This indicates 




Figure 11. (A) Dissolution of PNC in PBS. (B) Kinetics of PTX precipitation in PBS. (C) 
PTX concentration in the sampled medium at each time point. Symbols indicate each 
replicate. (D) Derived count rate of PNC and PPT suspended in 0.2% PBST. 
 
2.3.4.2 Limitations of Current Dissolution Kinetics Study Methods and Potential 
Alternatives 
Our release kinetics demonstrated a critical limitation of dialysis as a sampling 
method in testing dissolution kinetics of particle formulations of PTX. Dialysis method is 
often preferred to centrifugation because centrifugation makes it difficult to resuspend 





the drug diffusion and involve drug adsorption, especially for poorly water-soluble drugs 
like PTX, causing underestimation of dissolution kinetics.  
Given these challenges, it is worthwhile to note several in-situ analytical 
techniques developed to measure the dissolved drug directly and non-invasively. An 
ultraviolet/visible (UV/Vis) fiber optic probe is a good example of real-time method in 
dissolution test [34-36]. However, this technique is only applicable when excipients do 
not interfere with analysis. Moreover, the utility of UV/Vis probe in the release kinetics 
study of nanoparticle is still limited because of the light absorbing potential of 
nanoparticles [37]. Electrochemical analytical methods were also explored but their 
application was restricted to electroactive drugs [38, 39]. A method based on the light 
scattering of micro/nano particles was implemented in determination of the dissolution 
rate of nanoparticles [40, 41]. A linear decrease of scattering intensity is expected if 
particles dissolves in the release medium with time. As indicated by our results, this 
approach was not suitable for large particles with inadequate count rates and high 
tendency of sedimentation. An alternative method could be using hydrogel to contain 
drug particles, thereby separating them from receptor medium [42].  
 
2.3.5 PTX Release Kinetics from HA Gel Formulations 
Due to the limitations of the dialysis method mentioned above, gel formulations 




2.3.5.1 In Tween/PBS under Sink Condition 
PNC and PPT were loaded in the HA gel, and the PTX release was tested in-vitro 
using Tween/PBS as release medium. We first attempted to compare the dissolution rates 
under a sink condition as defined by the United States Pharmacopeia (the volume of 
medium at least three times that required to form a saturated solution of a drug [29]). 
Since the highest PTX concentration (1.1 µg/mL) in the release medium fell far below the  
limit of quantitation (3.8 µg/mL) which was calculated per the ICH guideline, the 
released amount was indirectly determined by measuring the PTX amount remaining in 
the gel at each time point and deducting it from the initial PTX amount. With this 
method, up to 80% of PTX was found to be released from the gels in 7 days, with no 
apparent difference between the two formulations (Fig. 12A).   
 
2.3.5.2 In Tween/PBS under Non-Sink Condition 
We next tested the dissolution rate in a non-sink condition to reflect the limited 
fluid volume in the peritoneal cavity. The volume of peritoneal fluid in a healthy adult is 
approximately 50 mL with a protein content 75% lower than that of the blood [44, 45]. 
The turnover rate of peritoneal fluid is 4-5 mL/h [44]. Although malignancies may 
increase the protein level and accelerate the volume and the turnover rate of the ascites, 
the small volume of the peritoneal fluid (compared to blood) is likely to challenge the 
sink condition assumption. Therefore, we used 20 mL of release medium (Tween/PBS) 
for PPT-gel and PNC-gel equivalent to 200 µg of PTX to create a release condition that 
intentionally violated a sink condition. The release medium was directly analyzed at each 
time point to determine the cumulative drug release. Under this non-sink condition, 
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32.6% and 30.6% of the total PTX were released from PPT-gel and PNC-gel, 
respectively, in 12 days (Fig. 12B). 66.0% (PPT-gel) and 59.7% of PTX (PNC-gel) were 
recovered in the remaining gel (Fig. 12C). The relatively slow release (compared to the 
sink condition) suggests that the released PTX might have undergone reprecipitation in 
the medium as the PTX concentration reached the saturation solubility. We expected that 
the two gels would show different release kinetics at least initially but did not observe 
any difference, most likely due to rapid reprecipitation that might have offset the effect of 




Figure 12. (A) In-vitro PTX release kinetics from HA-gel under sink condition (initial 
PTX concentration=1.1 µg/mL). (B) In-vitro PTX release kinetics from HA-gel under 
non-sink condition (initial PTX concentration=10 µg/mL). (C) Total PTX recovery from 
Tween/PBS medium. Data are expressed as averages and standard deviations of three 
independently and identically prepared samples. 
 
The lack of difference in in-vitro release kinetics between the two gels may be 
attributable to several reasons. First, both methods may involve the centrifugation-
induced artifacts. In the sink condition method, it is possible that the remaining PTX at 




the centrifugation, which would have pressurized the gel and caused artificial release of 
PPT and PNC loosely associated with the gel. In the non-sink method, the centrifugation 
force applied to separate the released PTX from the gels might have contributed to 
underestimation by accelerating the aggregation of reprecipitates.  Second, the 
invasiveness of Tween80 might also have masked the potential difference between two 
gels. In this regard, it is worthwhile to reconsider the utility of in-vitro release kinetics 
studies in predicting in-vivo outcomes. The release kinetics is largely affected by the 
sampling method, concentration gradient between the formulation and release medium 
(i.e., whether it satisfies the sink condition or not) and the choice of release medium [30]. 
However, the sampling method involves the aforementioned artifacts, and the sink 
condition assumption is not necessarily applicable to drug release in the peritoneal cavity 
due to the limited fluid volume and delay in systemic absorption of the dissolved drug. 
Tween/PBS is widely used as a dissolution/release medium for poorly water-soluble drug 
formulations to ensure the solubility [46-51]; however, its physiological relevance is not 
clearly established, and the active role of Tween80 in drug release is seldom considered 
in data interpretation.  
 
2.3.5.3 In FBS/PBS or Tween/PBS containing Hyaluronidase under Non-Sink 
Condition 
In-vitro PTX release kinetics was studied with a medium simulating the peritoneal 
cavity environment, which contains amphiphilic solutes (plasma proteins or Tween80) 
and hyaluronidase: 25-FBS/PBS with 10 U/mL HAase or Tween/PBS with 10 U/mL 
HAase. We were curious if HAse decelerated PTX release by degrading the gels and 
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facilitating the particle aggregation. The total PTX concentration in the media was kept at 
10 µg/mL, above the PTX solubility in Tween/PBS (3.3 µg/mL). PTX solubility in 25-
FBS/PBS was not measured, but given that PTX solubility in 50-FBS/PBS was 35 
µg/mL, so PTX solubility in 25-FBS/PBS was likely to be lower than 35 µg/mL. Thus, 
both tests were done under a non-sink condition.  
HA gel gradually degraded in 6 days in the presence of HAase. PPT-gel and 
PNC-gel continuously released 35.2% and 29.5% over 10 days in 25-FBS/PBS, 
respectively, similar to those tested without HAse (Fig. 13A). This indicates that the PTX 
reprecipitation dominated the potential effect of HAse. The PTX recovery from PNC or 
PPT-gel was much lower (< 60%) than that in Tween/PBS, probably due to the poor 
stability of PTX in serum containing medium and inadequate sampling frequency after 
the first day of the release kinetics study (Fig. 13B).  
Similarly, PPT-gel and PNC-gel released 32.7% and 29.6% over 10 days in 
Tween/PBS, respectively (Fig. 13C). Total PTX recovery from PNC or PPT-gel (~70%) 
was higher than that in 25-FBS/PBS reflecting the stability profile (Fig. 13D). On the 
other hand, this was lower than that in Tween/PBS without HAse (above 90%, Fig. 12C). 
This difference is not due to the effect of HAse but more likely due to the sampling 
condition. Here, the samples were centrifuged at 2095 rcf (as opposed to 9300 rcf in 
section 1.2.9.2), which might have caused incomplete separation of supernatant and 






Figure 13. (A) In-vitro PTX release kinetics performed in 25-FBS/PBS with 10U/mL 
HAase. (B) Total PTX recovery from 25-FBS/PBS medium (n=3). (C) In-vitro PTX 
release kinetics performed in Tween/PBS with 10U/mL HAase. (D) Total PTX recovery 
from Tween/PBS medium (n=3).  
  
2.3.6 PTX Release Kinetics from HA-EtCA-CMC Gel 
PTX release from HA-EtCA0.1-CMC gel was tested under non-sink condition. 
Although reprecipitation of PTX is likely to have played a dominant role in PTX release 
kinetics from the gel formulations in the non-sink condition, we speculated that the 
segregation of PNC within the gel might further decelerate drug release during 





















acid would create domains for PNC to dwell in and prevent segregation of PNC in the gel 
during the delivery period. As expected, HA- EtCA0.1-CMC gel increased to 31.8%, as 
compared to 19.5% from HA gel in 10 days (Fig. 14A). Total PTX recovery was also 
improved from 30.5% in HA gel to 45.2% in EtCA0.1-CMC-HA gel (Fig. 14B). This 
result suggested that PTX release was facilitated by incorporating hydrophobic domains 




Figure 14. (A) In-vitro PTX release from PNC containing HA gel or EtCA0.1-CMC-HA 
gel. (B) Total PTX recovery from Tween/PBS medium (n=3).  
 
2.4 Conclusions 
We have developed a nanoparticle depot for IP chemotherapy consisted of PNC 
and HA gel. PNC with a size of ~310 nm was produced by nonsolvent and temperature 






hydrophilic HA gel, a hydrophobic moiety, EtCA, was conjugated on CMC-CHO and 
employed as a partial replacement of HA-CHO. Dissolution kinetics of PNC could not be 
determined by the dialysis method due to drug reprecipitation caused by diffusion barrier, 
while fast dissolution of PNC was observed with light scattering method. PTX release 
profiles from PNC-gel and PPT-gel were estimated in both sink- and non-sink conditions, 
where the latter simulated the peritoneal environment. In-vitro release kinetics studies did 
not reveal any difference between PNC-gel and PPT-gel, partly due to the centrifugation-
related artifacts. Despite the technical limitations, in-vitro release kinetics studies 
detected enhancement of PTX release due to the inclusion of EtCA in the gel, indicating 
that hydrophobic domain in the gel helped prevent segregation of PNC. However, due to 
the unexpected toxicity of EtCA-CMC-CHO, EtCA-CMC-HA gel was not further 
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CHAPTER 3. BIOACTIVITY EVALUATION OF NANOPARTICLE DEPOT 
3.1 Introduction  
Although the difference in in-vitro release profile between PNC-gel and PPT-gel 
was not identified, it is still possible that PNC-gel can demonstrate potential advantages 
over PPT-gel in a more biologically relevant experimental setting or in-vivo because the 
in-vitro release kinetics does not always correlate well with the in-vivo outcomes. In this 
chapter, the half maximal inhibitory concentrations (IC50) of PTX in the form of PNC or 
PPT were measured with different cell viability assays on SKOV3 human ovarian cancer 
cells. Low IC50 value could be attributed to fast drug release as well as sensitivity of the 
cells to the drug. In addition, Maximum tolerated doses (MTD) of PPT-gel and PNC-gel 
were estimated using healthy mice to determine the PTX dose in in-vivo efficacy study 
and observe the difference in drug release rate in-vivo. In anti-tumor efficacy study, PNC 
was administered IP to nude mice bearing peritoneal ovarian tumor xenografts with the 
HA gel as a carrier to retain the drug in the peritoneal cavity. Progression of tumor 
burden after single treatment of PNC-gel was monitored over 10 weeks via non-invasive 
whole body imaging, and the outcome was compared with that of PPT-gel. We expect 




3.2 Materials and Methods 
3.2.1 Materials 
Hyaluronic acid (HA, 20 kDa and 500 kDa) was purchased from Lifecore 
Biomedical, LLC (Chaska, MN, USA). Paclitaxel (PTX) was a gift of Samyang Genex 
Corp (Seoul, Korea). Carbamazepine was purchased from Enzo life sciences (Plymouth 
Meeting, PA, USA). Cremophor ELP was a gift from BASF (New York, NY, USA). D-
Luciferin potassium salt was purchased from Gold Biotechnology (St. Louis, MO, USA). 
Geneticin® selective antibiotic (G418 sulfate, 50 mg/mL) was purchased from Life 
technologies (Grand Island, NY, USA). Cell culture medium and supplements were 
purchased from Invitrogen (Carlsbad, CA, USA). Micro BCA Protein Assay Kit was 
purchased from Life technologies (Grand Island, NY, USA). CellTiter-Glo® 2.0 Assay 
Kit was purchased from Promega (Madison, WI, USA). All other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
3.2.2 Determination of IC50 of Taxol, PPT and PNC on SKOV3 Cell Line 
IC50 of PNC on SKOV3 cell line was determined with luminescent cell viability 
assay (CellTiter-Glo® 2.0 Assay) which determines the number of viable cells by 
quantitating the amount of ATP from metabolically active cells. SKOV3 human ovarian 
cancer cells (ATCC) were maintained in RPMI-1640 medium supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were plated in a 96-well 
plate at a density of 5,000 cells per well with 0.2 mL of complete medium. After 24h 
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incubation, Taxol, PPT or PNC suspended in 22 µL PBS was added to each well and the 
final PTX concentration ranged from 0.05 to 100 nM. Control groups were treated with 
22 µL PBS or Cremophor ELP in PBS at the same concentrations as Taxol treated group. 
Cells were exposed to treatments for 24h and allowed to recover for 2 days after 
replacing the treatments with fresh medium. One hundred microliters of CellTiter-Glo 
Reagent was added to each well after removal of 100 µL of medium on the top. The plate 
was placed on an orbital shaker for 2 minutes to induce cell lysis and incubated at room 
temperature for 10 minutes to stabilize the luminescent signal. The luminescence of each 
treatment group was measured with a SpectraMax M3 microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) and normalized to the signal of PBS control group.  
 
3.2.3 Cellular Retention and Cytotoxicity of PTX 
SKOV3 human ovarian cancer cells (ATCC) were maintained in RPMI-1640 
medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin. Cells were plated in a 12-well plate at a density of 200,000 cells per well 
with 0.8 mL of complete medium. After 24h incubation, PNC or PPT suspended in 88 µL 
PBS was added to each well to make the final PTX concentration 6 µg/mL (7 µM). A 
control group was treated with 88 µL PBS. Cells were incubated with the treatments for 
3h and washed twice with 0.5 mL complete medium after removal of the treatments. The 
treated cells were incubated for two days in fresh medium and evaluated with the MTT 
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. The absorbance 
of the solubilized formazan was measured with a SpectraMax M3 microplate reader 
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(Molecular Devices, Sunnyvale, CA, USA) at a wavelength of 562 nm. The measured 
absorbance was normalized to the absorbance of the control group.   
To determine PTX retained in the cells after each treatment, SKOV3 cells were 
treated in the same way as described above. Immediately after removing treatments, 1 
mL of sterile water was added to each well, frozen and thawed once to lyse the cells. The 
cell lysate was analyzed with HPLC (see section 2.2.5) and Micro BCA assay to 
determine the concentrations of PTX and protein, respectively.  
PTX in the cell lysate was analyzed after ethyl acetate extraction. Briefly, 2 mL of 
the cell lysate was spiked with 10 µg/mL carbamazepine as an internal standard, mixed 
with 6 mL ethyl acetate, and agitated on a rotating shaker for 40 min. The mixture was 
then centrifuged at 3724 rcf for 15 min to separate an organic layer, which was 
transferred to a new glass vial and dried under vacuum. The dried sample was dissolved 
in HPLC mobile phase, filtered through 0.45 µm syringe filter, and analyzed with HPLC. 
A calibration curve was drawn with PTX in FBS medium in known concentrations, 
treated in the same manner as the sample solutions. PTX was analyzed with HPLC 
equipped with UV detector (1100 series, Agilent Technologies, Palo Alto, CA) and an 
Ascentis C18 column (25 cm × 4.6 mm, particle size 5 µm) (Supelco, St. Louis, MO, 
USA). The mobile phase was a mixture of acetonitrile and water (50:50), run in the 
isocratic mode at a flow rate of 1 mL/min. PTX was detected at 227 nm.  
In a separate experiment, SKOV3 cells were plated in a 12-well plate at a density 
of 60,000 cells per well with 1.5 mL of complete medium. After 24h incubation, a 
Transwell insert was suspended in each well as a container of PTX treatment. The 
Transwell membrane was perforated with fifteen 21-gauge needle holes to facilitate the 
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transport of released PTX (either as free molecules or particles) to the underlying cell 
layer. 0.1 mL of PNC-gel, PPT-gel, PNC, or PPT suspension was placed in each well 
along with 0.4 mL PBS, making the final PTX concentration in the well 30 µg/mL (35 
µM). A control group was treated with 0.1 mL of PBS. Cells were incubated with the 
treatments for 3h, 24h or 48h, removed of the treatments, washed twice, and incubated 
for additional two days in complete medium prior to the MTT assay. The solubility of 
PTX in the culture medium containing 10% FBS was determined in the same method as 
PBS containing 50 v/v% FBS described in Chapter 2.  
 
3.2.4 Determination of the Maximum Tolerated Doses of Treatments 
All animal procedures were approved by Purdue Animal Care and Use 
Committee, in conformity with the NIH guidelines for the care and use of laboratory 
animals. The MTD of each treatment was determined according to the method published 
by the National Cancer Institute’s Developmental Therapeutics Program [1]. Healthy 
female Balb/c wild-type mice (8-10 week old, ~20g, Harlan Laboratories, Indianapolis, 
IN, USA) were randomly assigned to Taxol, PPT-gel, and PNC-gel groups and given a 
single IP injection of each formulation at different dose levels (one mouse per dose). The 
mice were observed over a period of 2 weeks after the injection. The highest dose 
tolerated without >20% weight loss or other signs of significant toxicity was designated 
as the MTD of each treatment. This experiment was repeated at least three times to 




3.2.5 In-vivo Efficacy Studies 
A mouse model of IP tumor was prepared as described in our previous study [2]. 
Luciferase-expressing SKOV3 cells (SKOV3-luc, donated by Prof. Glen Kwon at 
University of Wisconsin-Madison) [3] were maintained in a complete RPMI-1640 
medium containing 500 µg/mL G418 sulfate. 107 cells were suspended in 1 mL RPMI-
1640 medium and IP injected to a female Balb/c nude mouse (8-10 week old, ~20g, 
Harlan Laboratories). Tumor growth was monitored every week by measuring the 
bioluminescence with the IVIS Lumina II whole body imaging system (Caliper Life 
Science, Hopkinton, MA, USA) [4]. When the radiance of tumors reached 105-106 
p/s/cm2/sr, which usually took one or two weeks, animals were evenly assigned to 5 
treatment groups (n=3 per group per study): PBS, HA gel, Taxol, PNC-gel and PPT-gel 
(equivalent to 30 mg/kg of PTX). One milliliter of each treatment was IP injected through 
a catheter, and the skin was sealed with GLUture topical tissue adhesive (Abbott Park, 
IL, USA).  Bioluminescence of IP tumor was measured weekly over 10 weeks. Animals 
were observed every 3 days for weight change and the signs of pain until they reached the 
criteria of sacrifice, which include the loss of appetite and/or body weight, bloated 
abdomen and signs of respiratory distress, according to the approved animal procedures.  
 
3.2.6 Statistical Analysis 
All in-vitro data were analyzed using GraphPad Prism 6 (La Jolla, CA), with 
unpaired t test to determine the difference of means between two groups. The comparison 
of survival curves was conducted with Log-rank (Mantel-Cox) test built in GraphPad 
85 
 
Prism 6. A value of p< 0.05 was considered statistically significant. For the tumor growth 
study, analysis of variance (ANOVA) was performed using IBM SPSS Statistics 23 
(Armonk, NY, USA) to test the differences between the treatment groups in the change of 
tumor burden over time.  
 
3.3 Results and Discussion 
3.3.1 IC50 of PTX in the Form of Taxol, PPT or PNC 
The growth profile of a certain cell line plays an important role in the 
determination of IC50 of a treatment. PTX interferes with the normal depolymerization of 
microtubules during cell proliferation [5, 6]. The population doubling time of SKOV3 
cell line was approximately 35h, which means that SKOV3 cells need at least 1.5 days to 
show their response to PTX. These indicate that it is necessary to leave SKOV3 cells in 
fresh medium for at least 1.5 days to observe the cytotoxic effect of PTX. However, this 
recovery time cannot be too long because challenged cells may become viable as before 
if the treatment discontinues, resulting in underestimation of PTX cytotoxicity. On the 
other hand, complete medium contains 10% FBS, which can solubilize PTX; thus, 
relatively long incubation time of PNC or PPT in the culture medium may diminish the 
potential difference in the release rate between PPT and PNC. Given these constraints, 
cells were exposed to each treatment for only one day, a time frame speculated to be 
short enough to observe differential PTX release from PPT and PNC, and incubated for 2 
more days in treatment-free medium to develop responses to the treatments. This 
experiment was repeated twice, and IC50 value was obtained with nonlinear regression 
86 
 
using GraphPad Prism 6. Although the apparent IC50 values increased in the order of 
Taxol, PNC, and PPT, reflecting the expected difference in dissolution rate of PTX, they 
did not show statistical difference, probably due to the variation of cell response to PTX 
(Fig. 15). Therefore, alternative study was carried out to directly quantitate the amount of 




Figure 15. IC50 of PTX on SKOV3 cell line in the form of Taxol, PPT and PNC (n=3).  
 
3.3.2 Cellular Retention and Cytotoxicity of PPT and PNC 
The cytotoxicity of PPT and PNC were compared as an indirect indicator of drug 
dissolution profiles. SKOV3 cells were incubated with PPT and PNC for 3h, and the level 
of PTX retained with cells were determined. Much less PTX was detected in the SKOV3 
cells treated with PNC than those with PPT (Fig. 16A). The relatively high level of PTX 
remaining in PPT-treated cells may be explained by the large size of PPT, which was not 
readily removed from cells by simple washing. Surprisingly, despite the low level of PTX 































fraction affected by the unit amount of PTX was 3.3 times greater for PNC than PPT 
(Fig. 16C), which indicates that PTX provided as PNC was much more efficient in 
killing SKOV-3 cells than PPT. These results suggest that PNC made PTX better 
available than PPT via the small size that facilitated the drug dissolution. In addition, the 
small size may have helped PNC to enter cells. A recent study supports that drug 
nanocrystals could be endocytosed as solid particles [7].  
 
3.3.3 Cytotoxicity of PPT-gel and PNC-gel 
Acknowledging aforementioned limitations of in-vitro release kinetics tests, we 
measured the cytotoxicity of PPT-gel and PNC-gel varying the exposure time to predict 
their in-vivo effects (Fig.16D). The gel was contained in a perforated Transwell insert to 
avoid direct contact with the cell layer that might limit oxygen supply. Free particles 
were supplied in the same manner to mimic a situation where a degrading gel was no 
longer able to retain the particles. Therefore, the tests with gels and free particles 
represented the initial and later phase of delivery, respectively. With 3h exposure, PNC-
gel was found to be more toxic than PPT-gel, indicating faster dissolution of PNC than 
PPT. This difference disappeared upon longer incubation (24h and 48h), which may be 
explained by the reprecipitation of released PTX exceeding the saturation solubility of 
PTX in the culture medium (1.4 µg/mL), as predicted from the release kinetics results.  In 
contrast, free PNC showed consistently high cytotoxicity as compared to PPT, indicating 
that at least part of PNC were endocytosed by the cells as solid particles before they 
underwent dissolution and reprecipitation in the medium. This result suggests that PNC-
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gel would achieve greater anti-tumor effect than PPT-gel in-vivo, as the endocytosis of 




Figure 16. (A) PTX retention normalized with total protein content. Micro BCA assay 
was performed to determine the total protein content in the cell lysate as an estimate of 
cell population. The PTX to protein ratio reflects PTX retained by each cell. (B) 
Cytotoxicity of PPT and PNC (equvilant to 7 µM PTX) to SKOV3 cells after 3h of direct 
exposure followed by incubation in drug-free medium. (C) Fraction of cells affected by 
unit amount of PTX. Data are expressed as averages and standard deviations of three 
measurements of a representative batch. Cytotoxicity of (D) PNC-gel and PPT-gel and 
(E) PPT and PNC (equivalent to 35 µM PTX) to SKOV3 cells after 3h, 24h or 48 h 
exposure followed by incubation in drug-free medium. Data are expressed as averages 
and standard deviations of three measurements of a representative batch. *: p<0.05 by t-
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3.3.4 Maximum Tolerated Doses of PTX Treatments 
MTDs of PNC-gel, PPT-gel, and Taxol were determined using healthy Balb/c 
mice for two purposes: (i) to determine the maximum PTX dose to administer in the anti-
tumor efficacy study and (ii) to observe the difference in drug release rate in-vivo. 
Specifically, we hypothesized that the gel more rapidly releasing PTX would have a 
lower MTD value. Mice did not survive a single administration at dose higher than 60 
mg/kg. On the other hand, PPT-gel and PNC-gel were tolerated much higher doses: 120 
mg/kg and 90 mg/kg, respectively. This result first confirms the benefit of the gel 
formulations free of Cremophor EL, which is associated with several adverse effects such 
as severe anaphylactoid hypersensitivity reactions, abnormal lipoprotein pattern and 
peripheral neuropathy [8]. Interestingly, PNC-gel showed lower MTD than PPT-gel, 
despite the identical composition. The difference between PNC-gel and PPT-gel suggests 
that PNC-gel might have released a greater amount of PTX than PPT-gel in the given 
time. This result is consistent with the cellular PTX retention and cytotoxicity results.  
 
3.3.5 Anti-tumor Effects of PPT-gel and PNC-gel 
The anti-tumor efficacy of PPT- and PNC-gels was studied using a mouse model 
of IP tumor. Once the tumor reached a certain size as indicated by the bioluminescence 
signals, treatments (Taxol, PPT-gel and PNC-gel) equivalent to 30 mg/kg PTX as well as 
vehicle controls were administered IP once. A single administration regimen was chosen 
to compare the duration of the therapeutic effects of the treatments (Fig. 17A). The tumor 
burden was monitored up to 14 weeks until the animals reach a humane endpoint (Fig. 
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17B). Animals treated with PBS or HA gel vehicle reached the endpoint in <7 weeks 
with median survival periods of 37 days. All animals receiving PTX-treatments survived 
longer than the vehicle control groups with notable difference according to the treatment. 
Tumor growth in animals treated with Taxol was initially delayed but resumed after 3 
weeks to reach the endpoint in <9 weeks with a median survival time of 56 days. This 
result may be explained by the rapid clearance of PTX from the peritoneal cavity [2]. 
Animals treated with PPT-gel showed a similar survival curve (median survival time of 
51 days) as Taxol-treated ones. On the other hand, mice treated with PNC-gel showed a 
significant extension of the survival period (67 days), which clearly contrasted with 
Taxol-treated groups (p<0.05: PNC-gel vs. Taxol, Log rank Mantel-Cox test) (Fig. 18A). 
Both PPT- and PNC-gel-treated animals showed minimal increase in tumor signals in 
surviving animals until 7 weeks post-treatment (Fig. 18B). However, it was difficult to 
obtain meaningful statistical analysis from averages of the bioluminescence values, due 
to the attrition of animals over the course of survival period and large variations in tumor 
growth. Thus, the change of tumor burden (tumor burden at each time point-initial tumor 
burden) was plotted with respect to the survival time for each mouse, and the area under 
the curve over time (AUC/time) was calculated as an average tumor burden for the mouse 
during the survival period. The mice treated with PNC-gel or PPT-gel showed the lowest 
median AUC/time value among the treatment (Fig. 19). The AUC/time value of Taxol 
group was not significantly different from PBS or HA gel control groups. Both PPT-gel 
and PNC-gel showed significantly lower AUC/time values than Taxol group, but the 
difference between PNC-gel and Taxol groups was more significant than that of PPT-gel 





Figure 17. (A) Treatment schedule. (B) Representative whole body bioluminescence 
imaging of animals administered with different treatments. The most representative 






Weekly monitoring of tumor growth












Figure 18. (A) Kaplan-Meier analysis for survival time post tumor cells inoculation. n=9 
per group. *: p<0.05, PNC-gel vs. Taxol by Log-rank Mantel-Cox test. (B) 
Bioluminescence of IP tumors in animals treated with PBS, HA gel, Taxol, PPT-gel, and 
PNC-gel. Data are expressed as median with ranges of surviving animals. The box 
extends from the 25th to 75th percentiles, the line in the middle of the box indicates the 
median, and the whiskers go down to the smallest value and up to the largest.  
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Figure 19. AUC of tumor burden change over survival time of animals treated with PBS, 
HA gel, Taxol, PNC-gel and PPT-gel. *: p<0.05, PPT-gel vs. Taxol, **: p<0.05, PNC-gel 
vs. Taxol by Tukey’s test. 
 
Taken together, the in-vivo studies demonstrated that a single dose PNC-gel was 
significantly better in delaying tumor progression as compared to Taxol, while PPT-gel 
was not different from Taxol in the median survival time. This result is consistent with 
the in-vitro cellular toxicity test and MTD values, which indicated greater dissolution and 
cellular uptake of PNC than PPT. Based on the depot effect of HA gel, PNC could have a 
prolonged effect on IP tumors than Taxol. It remains to be investigated how the 
prolonged local delivery improved the efficacy of PTX. A potential mechanism may 
involve the tumor priming effect by initial PTX exposure, which suppresses stroma 
expansion [9], thereby facilitating the transport of subsequently released PTX. A 
remaining challenge is to improve the specificity of local delivery of PTX. The current 
PNC-gel does not have a mechanism to distinguish tumors vs. normal tissues; thus, some 
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observed on macroscopic level in this study). This may be achieved by surface 
modification of PNC with cell-specific ligands.  
 
3.4 Conclusion 
PTX-gel formulation comprising PNC and HA gel was developed for IP 
chemotherapy of ovarian cancer. In cellular toxicity test and MTD assessment, PNC-gel 
provided more efficient killing effect and greater toxicity than PPT-gel, which contained 
larger PTX particles, indicating a greater dissolution rate of PNC due to the small size. A 
single IP administration of PNC-gel extended the survival of mice with IP tumors 
significantly better than the same dose Taxol, due to the local depot effect, whereas PPT-
gel was not superior to Taxol in survival extension. While the cell toxicity test and in-
vivo results consistently point to the beneficial effect of particle size reduction, in-vitro 
drug release kinetics did not predict the difference between PPT- and PNC-gels, 
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CHAPTER 4. ALBUMIN-STABILIZED PACLITAXEL NANOCRYSTALS 
4.1 Literature Review3 
Approximately 40% of active pharmaceutical ingredients in the discovery stage 
have poor water-solubility [1]. In order to attain adequate bioavailability of poorly 
soluble drugs, special formulation strategies are employed to increase their dissolution in 
aqueous medium [2]. Traditionally, organic solvents are used as co-solvents [3] or a part 
of emulsion [4] to formulate the poorly soluble drugs as aqueous dosage forms. 
Alternatively, the drug is fitted in cyclodextrins, which have a hydrophobic interior and a 
hydrophilic exterior, and made soluble in water [5]. Another way of enhancing the 
solubility of poorly soluble drugs is to produce nanoparticulate formulations, such as 
liposomes [6], micelles [7], nanoemulsion [8], solid lipid nanoparticles [9], and 
polymeric nanoparticles [10]. However, relatively low drug loading efficiency, concerns 
for the safety of excipients, and complicated manufacturing process are noted as potential 
disadvantages of these strategies.  
Nanocrystallization is a technique to produce crystalline particles of poorly 
soluble drugs in the nanometer range (i.e., nanocrystals). Due to the size and, thus, the 
high surface area to volume ratio, nanocrystals can increase the saturation solubility of a 
                                                 
3 Reprinted from Current Opinion in Solid State & Materials Science, 16(6), Bo Sun, Yoon Yeo, 
Nanocrystals for the parenteral delivery of poorly water-soluble drugs, p 295-301, Copyright (2015), with 
permission from Elsevier.  
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drug and the dissolution rate of drug particles [11]. Nanocrystals have gained increasing 
interest in the pharmaceutical industry because of the simple structures and compositions. 
They have been explored for a variety of therapeutic applications including oral [12], 
dermal [13], pulmonary [14], systemic administration [15], as well as targeted drug 
delivery [16] and intraperitoneal chemotherapy [17]. The objective of this section is to 
review the production of nanocrystals and discuss the remaining challenges in the 
development of nanocrystal products.  
 
4.1.1 Production of Nanocrystals 
Nanocrystals of poorly soluble drugs can be created by “top-down” or “bottom-
up” technologies (Fig. 20), or combinations of the two [18]. Nanocrystals are produced 
from the drug itself, with surfactants or polymeric stabilizers on the surface; thus, the 
drug content in nanocrystals approaches 100% [18]. The production of nanocrystals is 
relatively easy to scale up and transfer to industry as compared to other formulations on 
the market, such as liposomes [19, 20] and albumin-based nanoparticles [21]. Several 
nanocrystal products, produced by wet milling and high-pressure homogenization, have 






Figure 20. Schematics of (A) bottom-up and (B) top-down production of nanocrystals. 
Aqueous dispersion of nanocrystals can be further proceeded into sterile products or other 
dosage forms.  
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Table 4. Examples of nanocrystal products for oral administration approved by the FDA 
[22, 23].  
Trade name (drug) Manufacturing 
techniques 
Indications Company 




Emend® (Aprepitant) Top-down, wet milling Antiemetic Merck & Co.  









Megace ES® (Megestrol 
acetate) 
Top-down, wet milling Antianorexic Par 
Pharmaceutical  


















Top-down, wet milling Muscle relaxant Acorda 
 
4.1.1.1 Bottom-up Technologies 
The bottom-up approach refers to methods that create small drug particles from 
drug molecules dissolved in an organic solution. Small drug particles are formed as drug 
molecules precipitate from solution in the presence of an agent and/or a condition that 
induces nucleation of the molecules. For example, a non-solvent, which is miscible with 
the solvent but does not dissolve the drug, is used to induce the nanocrystal formation, in 
conjunction with various methods to mix the drug solution with non-solvents such as 
rotation, liquid jets, or multi-inlet vortex mixing [24]. Alternatively, supercritical fluid, 
101 
 
ultrasonic waves, or controlled solvent evaporation are employed to induce drug 
precipitation. These technologies are discussed in  detail in a recent review article [24].  
 Particles produced by the bottom-up approach can be crystalline or amorphous. 
Amorphous nanoparticles produced by a technique called NanomorphTM achieve higher 
saturation solubility and faster dissolution rate than nanocrystals [25, 26]. However, they 
are prone to partial or complete re-crystallization, which may lead to decreased 
bioavailability. Due to the stability and consistent performance, nanocrystals are usually 
favored over amorphous particles. On the other hand, the production of nanocrystals 
within a desired size range depends critically on precise control of the precipitation and 
prevention of the crystal growth during the production [18]. The complexity of the 
process control and potential risk of residual organic solvents have discouraged the 
development of commercial products [22]. Recently, spray-drying [27] and freeze-drying 
[28, 29] processes have been used to achieve continuous control of the crystallization at 
large scales. 
 
4.1.1.2 Top-down Technologies 
Top-down approach is based on two basic size reduction methods: wet milling 
[30] and high-pressure homogenization [31]. The wet milling process applies shear stress 
on large drug particles by grinding an aqueous suspension that contains a drug and a 
surface stabilizer using beads or pearls in a milling chamber [32]. The outcome of the 
milling process is determined by the hardness of the drug, energy input, milling time, and 
stabilizer concentration [32]. Microfluidization and piston-gap homogenization are 
examples of high-pressure homogenization [18]. Microfluidization is based on the jet 
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stream principle, where the size diminution is achieved by collision of two fluid streams 
of particle suspension in a Y-type chamber under high pressure [22, 31]. The piston-gap 
homogenizer forces a particle suspension to pass a small gap (~5 µm) under pressure. 
The high shear forces, turbulent flow, and cavitation generated during this passage can 
reduce the particle size to the nanometer range [22, 31]. The performance of this process 
depends on the number of cycles, power density, and temperature [31]. These techniques 
are widely used in industry.  
 Compared to bottom-up methods, top-down methods require higher energy 
consumption and a longer operation time. The risk of contamination due to the erosion of 
milling beads is also a disadvantage of wet milling [33]. Moreover, the high-energy 
process may induce phase transition of a drug, which may compromise the in-vivo 
performance of the products [34].  
 
4.1.1.3 Combined Technologies 
A pre-treatment step (bottom-up) and particle size reduction step (top-down) may 
be combined. For example, precipitates are first obtained from anti-solvent precipitation, 
spray-drying, or lyophilization (pre-treatment step), followed by high-pressure 
homogenization (particle-size reduction) [18, 22]. One of the roles of the high-pressure 
homogenization step is to anneal the initial precipitates, which are often 
thermodynamically unstable, into an ordered crystal structure [22]. Two well-established 
techniques, NANOEDGETM and smartcrystals®, have been discussed elsewhere in detail 




4.1.1.4 Nanocrystal Stabilization 
Due to the high surface energy generated by nanonization, surface stabilizers are 
needed to prevent aggregation and precipitation of nanocrystals. Examples of stabilizing 
systems are summarized in a recent review article [23]. For drug nanocrystals with no 
surface charge, anionic surfactants such as sodium cholate, sodium deoxycholate, and 
sodium lauryl sulfate are often used to keep the particles separated via electrostatic 
repulsion. Another way of stabilizing nanocrystals is to apply polymeric stabilizers on 
their surface and establish a steric barrier against aggregation. Polymers used for this 
purpose are derivatives of cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, 
Polysorbates (polyoxyethylene sorbitan fatty acid esters), and Pluronics (or Poloxamers, 
triblock-copolymers of polyoxyethylene and polyoxypropylene) [35, 36]. Some of the 
stabilizers, such as arginine, amphiphilic amino acid copolymers, and vitamin E 
polyethylene glycol succinate (TPGS), are biologically active and provide additional 
functions to the nanocrystals [30]. For example, TPGS, an effective P-glycoprotein 
inhibitor [37], enables paclitaxel (PTX) nanocrystals to overcome multidrug resistance 
[38]. The effectiveness of PTX nanocrystals stabilized with TPGS was demonstrated in a 
nude mouse model bearing multidrug-resistant NCI/ADR-RES human ovarian cancer 
cells [38].   
 The effectiveness of a nanocrystal stabilizer depends on its affinity for a drug, the 
concentration, and the stabilizer to drug ratio in suspension. Relatively hydrophobic 
stabilizers have higher affinity for drug crystals and a greater stabilizing effect [39]. 
There is a positive correlation between particle size and the hydrophilic lipophilic balance 
(HLB) value of a non-ionic surfactant in bottom-up approaches; thus, the HLB value can 
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be a useful guideline for the selection of a stabilizer [40]. Typically, a surfactant with a 
low HLB value (lipophilic surfactant) is a good stabilizer of hydrophobic nanocrystals. 
Adequate surface coverage by stabilizers, irrespective of their mechanisms, is critical to 
the stabilization of nanocrystals. However, it does not necessarily mean that the stability 
increases in proportion to the concentration of a stabilizer. When the concentration of a 
surfactant exceeds the critical micelle concentration (CMC), the excessive surfactant has 
a negative effect on the stability of the nanocrystal suspension (nanosuspension) because 
micelle formation begins to compete with adsorption to the nanocrystal surface [41-43].  
 
4.1.2 Remaining Challenges in Nanocrystal Development for Parental Applications 
4.1.2.1 Instability during Storage 
Ostwald ripening refers to a phenomenon that small particles gradually dissolve 
and redeposit on the surface of larger particles over time (Fig. 21) [44]. It occurs when 
the particle size in a dispersion system is heterogeneous and the dispersed phase (drug) 
has a limited solubility in the medium (water) [45], which, unfortunately, are the 
conditions frequently encountered in pharmaceutical suspensions [46, 47]. Ostwald 
ripening leads to the particle size growth and physical instability of a dispersion system 






Figure 21. Schematic representation of Ostwald ripening in nanosuspension. 
 
 Surfactants and polymers are commonly used as stabilizers to delay detachment 
and attachment of drug molecules at the surface of dispersed particles [45]. Polymers are 
believed to be more effective than small molecular-weight surfactants because they tend 
to adhere to the nanocrystal surface less dynamically than surfactants [48]. Another way 
of preventing particle size growth is to produce uniform nanocrystals, thus eliminating 
one of the conditions for Ostwald ripening. Optimizing the process parameters, such as 
the number of high-pressure homogenization cycles [49], milling time [34, 50] and 
milling speed [51], can eliminate large particles and obtain narrow size distribution. 
Processing nanosuspensions into solid products is another way of avoiding dynamic 
changes in the medium and thus Ostwald ripening [23, 52].  
 
4.1.2.2 Instability during Applications 
Due to the high surface area to volume ratio, complete dissolution of nanocrystals 
can occur quickly (in less than an hour) as long as a sink condition is maintained (Table. 
5). On the other hand, in locations with a limited volume of fluid, such as the peritoneal 
cavity, stomach, or the lungs, nanocrystals may be exposed to a non-sink condition for an 
Nanocrystals with different 
particle sizes
Drug molecules gradually 
transfer from small particles 
to large particles.
Large particles grow 
continuously at the expense of 




extended period of time. This may limit the dissolution rate of the nanocrystals and 
provide an opportunity for sustained drug release [16]. However, with the gradual surface 
erosion and loss of stabilizing agents, the nanocrystals may become increasingly unstable 
and, thus, undergo agglomeration and Ostwald ripening over time. When this occurs, 
drug dissolution slows down significantly, to an extent that the drug is no longer 
bioavailable. We have experienced a consequence of particle agglomeration in an animal 
model of IP tumors [53]: we produced PTX particles with precipitation followed by 
sonication and administered the particles IP into mice bearing ovarian tumors in the 
peritoneal cavity, using an in-situ crosslinkable hyaluronic acid-based hydrogel as a 
carrier [53]. The PTX precipitates delivered with the hydrogel were best retained in the 
peritoneal cavity as compared to other formulations, which included multiple injections 
of Taxol, a bolus injection of Taxol, PTX precipitates alone, and Taxol delivered with the 
hydrogel. Despite the prolonged IP retention, the anti-tumor effect of hydrogel-embedded 
PTX precipitates was not significantly different from the others, which were cleared from 
the peritoneal cavity much earlier. One of the possible explanations is the agglomeration 










Table 5. Examples of nanocrystal dissolution in a sink condition.  
Drug Particle size (nm) Dissolution rate Reference 
Oridonin 322.7  98% dissolved in 24 min [41] 
Asulacrine d(v; 0.5)* 133 ± 20 42% dissolved in 6 h [15] 
Celecoxib d(v; 0.5) 360 91.8% dissolved in 50 min [54] 
Meloxicam d(v; 0.5) 530 ± 110 100% dissolved in 10 min [55] 
Artemisinin 100-360 75.9% dissolved in 4 h [56] 
Nitrendipine 209 ± 9 90% dissolved in 2 min [57] 
Quercetin 213.6 ± 29.3 73.2% dissolved in 20 min [58] 
Itraconazole ~300 85% dissolved in 90 min [12] 
Camptothecin 200-700 50% dissolved in 2 h [16] 
*Note: size of the particles for which 50% of the same volume contains particles smaller 
than d (v; 0.5).   
 
4.1.2.3 Lack of Target Specificity 
The surface of nanocrystals is decorated with specific ligands for target-specific 
delivery. However, continuous surface erosion poses a challenge to the longevity of the 
targeting effect. In this regard, it is worthwhile to note a recent approach to produce a co-
crystal of a drug and functional molecules [59]. Here, Li et al. produced hybrid crystals 
by co-crystallization of PTX and fluorescent dyes, where guest dye molecules were 
integrated in PTX nanocrystals [59]. Since the dye was embedded throughout the matrix, 
the PTX-dye hybrid nanocrystals could be located via real-time imaging during their 
lifetime in the body. The same principle is applicable to producing drug-ligand hybrid 





While the design of nanoparticulate formulations has become increasingly 
sophisticated, structurally and conceptually simple nanocrystals have a unique advantage 
with respect to the development of commercial products. Nanocrystals can greatly 
enhance the dissolution rate of poorly soluble drugs. The large contact area of 
nanocrystals can allow for a greater interaction with tissue or cell surfaces and enhance 
drug absorption. Several oral nanocrystal products are available on the market and dermal 
and IV products are actively explored. However, the potential of nanocrystals has not 
been thoroughly investigated for different applications such as targeted or local drug 
delivery. For example, nanocrystals can be combined with implantable delivery systems 
to attain a higher local concentration for a prolonged period of time. This requires 
nanocrystals to maintain the small size during long-term delivery without using toxic 
surfactants as surface stabilizers. Current methods of nanocrystal production do not 
adequately address the challenges in development of such products, and new approaches 
to engineer nanocrystals are strongly awaited.  
To overcome the limitations in current nanocrystal production for local therapy, 
we developed a method to make PTX nanocrystals smaller than 200 nm with albumin as 
a surface stabilizer. Albumin was chosen because of its ability of adsorbing onto 
hydrophobic surfaces and therefore provides steric hindrance to nanocrystal aggregation 
and growth [60, 61]. Moreover, serum proteins have the ability to bind certain membrane 
proteins which may facilitate targeting of anticancer drugs to the tumors [62, 63]. This 
method involves crystallization in a matrix of surfactant, such as Pluronic F127. The 
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presence of polymer matrix limits the growth of crystals; thus, this method can form 
relatively small particle size (<200 nm). The incipient nanocrystals (iCim) are harvested 
by sonication and hydration and stabilized with surface modifiers such as albumin. 
Pluronic F127 is replaced by the surface modifiers with higher affinity for nanocrystals 
and mostly absent in the final product. Due to the small size and the lack of polymeric 
surfactant, it is expected to provide faster dissolution of a drug and greater safety than 
other nanocrystal formulations.  
 
4.3 Materials and Methods 
4.3.1 Materials 
Paclitaxel (PTX) was a gift of Samyang Genex Corp (Seoul, Korea). Pluronic 
F127 was a gift from BASF (New York, NY, USA). Albumin from human serum (alb, 66 
kDa, ≥ 96%) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Reagents for 
sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel electrophoresis were purchased 
from Bio-Rad (Hercules, CA, USA). Micro BCA Protein Assay Kit was purchased from 
Life technologies (Grand Island, NY, USA). All other reagents were purchased from 




4.3.2 Preparation of Albumin-stabilized PNC 
4.3.2.1 Crystallization in Matrix (Cim) 
Crystallization in Matrix consists of two steps: first, incipient crystallization in 
matrix  (iCim), adapted from the literature [64]; second, surface stabilization of iCim.  
Incipient Crystalliation in Matrix (iCim): PTX was crystallized in the polymeric 
matrix and recovered by sonication and hydration (Fig. 22). Briefly, 6 mg PTX and 24 
mg Pluronic F127 (1/4, w/w) were fully dissolved in 3 mL of chloroform in a round 
bottom flask. Chloroform was evaporated with rotary evaporator at 40 ℃ for 2 hours to 
form a thin film on the wall of the flask. Six milliliters of DI water was added to hydrate 
the film under stirring at room temperature for 1hour. The hydrated suspension was 
sonicated with ice-water bath to help reduce the particle size. The settings of the probe 
sonicator were: power = 40%, time = 15 min and pulse = 1s/1s.  
Surface Stabilization of iCim: iCim was stabilized with albumin. iCim suspension 
(PTX concentration = 1 mg/mL) was mixed with an equal volume of aqueous albumin 
aqueous solution (8 mg/mL) and incubated at room temperature for 3 hours on a rotating 
rocker. The mixture was centrifuged at 4 ℃ at 104 rpm (9300 rcf) for 10 min to remove 
Pluronic F127 and unadsorbed albumin. The pellet was re-suspended with 0.5 mg/mL 
albumin solution, and the surface stabilized nanocrystals were collected by centrifugation 





4.3.2.2 Nonsolvent and Temperature-Induced Crystallization 
Control nanocrystals were prepared by the bottom-up method based on 
nonsolvent and temperature-induced crystallization [59] (Section 2.2.2) and referred to as 
PNC. To further stabilize PNC, PNC suspension (1 mg/mL) was mixed with an equal 
volume of aqueous albumin solution (2 mg/mL) and incubated at room temperature for 
1.5 hours on a rotating rocker. The albumin-coated PNC (PNC-alb) was collected by 
centrifugation at 4 ℃ at 104 rpm (9300 rcf) for 15 min and washed with deionized (DI) 




Figure 22. Diagram of preparation of Cim-alb.  
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4.3.3 Characterization of Nanocrystals 
The particle sizes of iCim, Cim-alb, PNC, and PNC-alb were measured in DI 
water with a Zetasizer Nano-ZS90 (Malvern instruments, Westborough, MA, USA). The 
morphology of lyophilized Cim-alb and PNC-alb was visualized with a FEI Nova 
nanoSEM field emission scanning electron microscopy (Hillsboro, OR, USA). Cim-alb 
and PNC-alb were sputter-coated with platinum for 1 min and observed with a high 
resolution through-the-lens detector under 5kV accelerating voltage and spot size 3. The 
protein content of Cim-alb or PNC-alb was determined with Micro BCA protein assay or 
gel electrophoresis.  
 
4.4 Results and Discussions 
4.4.1 Nanocrystal Morphology 
PNC-alb showed a rod-shape with a length of ~400 nm and a width of ~150 nm 
under SEM (Fig. 23A). Cim-alb showed a similar shape as PNC with a length of ~500 






Figure 23. Scanning electron micrograph of lyophilized (A) PNC-alb and (B) Cim-alb. 
Scale bar: 500 nm.  
 
4.4.2 Nanocrystal Size 
The size difference visualized in SEM was reflected in DLS measurement. The 
average diameter of iCim measured by DLS was 157.1 nm.  With surface stabilization 
with albumin, Cim-alb had an average diameter of 186.4 nm (Table 6). The initial size 
increase was induced by centrifugation, but Cim-alb withstood subsequent centrifugation 
with no further size increase. The average diameter of PNC was 301.3 nm. With albumin 










Table 6. Particle size of albumin-stabilized PNC and intermediate products.  
 Size (nm)* Polydispersity index range 
Min. Max. 
iCim (n=8) 157.1 ± 14.6 0.079 0.226 
Cim-alb after first centrifugation 
(n=9) 
188.7 ± 24.6 0.052 0.313 
Cim-alb after second centrifugation 
(n=2) 
186.4 ± 18.1 0.126 0.209 
PNC (n=5) 301.3 ± 17.9 0.049 0.362 
PNC-alb (n=7) 335.5 ± 19.7 0.152 0.372 
*: average diameter and standard deviation of n batches prepared independently and 
identically.  
 
The protective effect of albumin was evident when PNC and PNC-alb were 
subjected to repeated centrifugation at 4 ℃ at 104 rpm (9300 rcf) for 10 min: bare PNC 
aggregated to form ~3 µm particles, while PNC-alb was kept at ~330 nm (Fig. 24). This 
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4.4.3 Albumin content 
The albumin contents in Cim-alb and PNC-alb were determined using standard 
Micro BCA protein assay. Four percent SDS aqueous solution was used to strip off the 
albumin from the nanocrystal surface. The weight ratio between PTX and albumin was 
8.21/1 (PTX loading % = 89.1%). However, PTX can interfere with BCA assay because 
of the secondary amino group in the structure. SDS-PAGE gel electrophoresis was 
recommended to determine the albumin content though the influence of PTX could be 
deducted in the BCA assay. The albumin content in iCim-alb was measured based on the 
correlation between albumin concentration and band intensity in SDS-PAGE gel 
electrophoresis. The weight ratio between PTX and albumin in iCim-alb was 6.3/1 (PTX 
loading % =85%) (With courtesy of Joonyoung Park).  
 
4.4.4 Proposed Role of Albumin in Cim-alb 
Cim-alb maintained original particle size after repeated centrifugation, whereas 
iCim (before albumin protection) could not be resuspended. This indicates albumin was 
present on the nanocrystal surface and prevented hydrophobic aggregation of the 
particles. The quantity of remaining Pluronic F127 after albumin adsorption has not been 
directly measured. Given that albumin and PTX account for 13.5% and 85%, 
respectively, the remaining Pluronic F127 is likely to be <2% (With courtesy of 
Joonyoung Park). There are two possible scenarios in albumin coverage of the 
nanocrystal surface: first, albumin added onto Pluronic F127 surface; second, albumin 
replacing Pluronic F127 on nanocrystal surface. Considering the low Pluronic F127 
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content in Cim-alb and improved size stability, second scenario should be the case though 
direct evident was still needed.  
 
4.5 Conclusion 
Albumin-stabilized nanocrystals with a sub-200 nm particle size were prepared 
using a method involving incipient crystallization in polymer matrix and subsequent 
surface stabilization with albumin. The presence of polymeric matrix limited the growth 
of crystals; thus, PTX could form nanocrystals at ~160 nm. The surface stabilized 
nanocrystals (Cim-alb) maintained particle size below 200 nm. Due to the reduced 
particle size and the lack of a surfactant, Cim-alb is expected to provide faster PTX 
dissolution and greater safety than conventional nanocrystal formulations. The function 
and quantitation of surface stabilizers need further investigation. In-vitro dissolution test 
and bioactivity evaluation of Cim-alb remains to be performed to test the contribution of 
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CHAPTER 5. CONCLUSION 
PTX was delivered as PNC via an in-situ crosslinkable HA gel, aiming to increase 
the retention and chemotherapeutic effect in the peritoneal cavity. Several attempts were 
made to evaluate the difference in dissolution rate between PNCs and uncontrolled 
precipitates (PPTs) using in-vitro conditions reflecting the peritoneal cavity, such as non-
sink condition and amphiphilic components.  The expected difference between PNC and 
PPT or gels containing the two was not clearly seen in the in-vitro release studies 
(Chapter 2). Nevertheless, PNC was more efficient in killing SKOV3 cells than PPT, and 
PNC-gel showed some advantage in anti-tumor efficacy on tumor bearing mice over 
PPT-gel. However, the heterogeneity of tumor growth and decreasing number of animals 
following the tumor relapse made it difficult to statistically differentiate PNC-gel from 
PPT-gel based on bioluminiescence imaging (Chapter 3).   
Although the cytotoxicity result and in-vivo anti-tumor effects demonstrate the 
PNC-gel demonstrated its effectiveness as an IP chemotherapy delivery system, the small 
extent of improvement over PPT-gel suggest that PTX dissolution was still limited in the 
non-sink condition of the peritoneal cavity. PNC-gel can be further improved at least in 
two aspects. First, it is possible that PNC may have segregated from the hydrogel matrix 
and formed aggregates during the prolonged incubation in hydrogel, further delaying the 
PTX release. To prevent PNC segregation, HA gel may be modified to improve the 
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compatibility with PNC. To this end, HA gel conjugated with a derivative of 5β-cholanic 
acid was synthesized, which would form hydrophobic domains to accommodate 
hydrophobic PNC (Chapter 2). The hydrophobically modified hydrogel improved PTX 
release, confirming that compatibility between PNC and hydrogel is an important factor 
in local delivery of PTX.  The current form of the hydrophobically modified hydrogel 
will not be pursued due to the unexpected toxicity of the gel precursor (EtCA-CMC-
CHO), but it will be worthwhile to synthesize an alternative hydrophobitized gel 
precursor with low toxicity. Second, PNC size may be further reduced to improve 
dissolution of PTX. PNC produced with nonsolvent and temperature induced 
crystallization method, used for the in-vivo study, and had an average diameter of ~ 260 
nm. Albumin-stabilization helped prevent aggregation of PNC but did not produce 
smaller PNC. A new method of producing smaller PNC has been developed, based on 
crystallization in surfactant matrix and surface stabilization with albumin (Chapter 4). 
This method involves forming sub-200 nm PNC with Pluronic F127 and replacing it with 
albumin for further stabilization. The function and quantitation of surface stabilizers on 
Cim-alb remain to be investigated.  
The future delivery systems may be built with hydrophobically modified 
hydrogels and/or Cim-alb NCs. Ultimately, their effectiveness in reducing IP tumor 
burdens needs to be tested in-vivo, but mechanistic understanding of the contributions of 
each component will depend on well-controlled in-vitro studies. This study identified the 
limitations of current in-vitro drug release kinetics in predicting the in-vivo outcome of 
different formulations. Ideally in-vitro release kinetics should not involve artifacts due to 
sampling procedures, such as centrifugation and dialysis, but should be easy to accurately 
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analyze. In this regard, it is worthwhile to note a promising method based on the linearity 
between light scattering intensity and the concentration of partially dissolved particles. A 
new release/dissolution kinetics test method will be highly beneficial with the advent of 
new drug delivery systems, in particular those including poorly water-soluble drugs for 
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